Venus Concept (VERO) 10-K 27 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 22, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001409269
Entity Registrant Name	Venus Concept Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-38238
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1681204
Entity Address, Address Line One	235 Yorkland Blvd. Suite 900
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	M2J 4Y8
City Area Code	877
Local Phone Number	848-8430
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	VERO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 18,128,723
Entity Common Stock, Shares Outstanding		79,991,130
Auditor Name	MNP LLP
Auditor Firm ID	1930
Auditor Location	Toronto, Canada

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 11,569	$ 30,876
Accounts receivable, net of allowance of $13,619 and $11,997 as of December 31, 2022, and 2021	37,262	46,918
Inventories	23,906	20,543
Prepaid expenses	1,688	2,737
Advances to suppliers	5,881	5,667
Other current assets	3,702	3,758
Total current assets	84,008	110,499
LONG-TERM ASSETS:
Long-term trade receivables	20,044	27,710
Deferred tax assets	947	284
Severance pay funds	741	817
Property and equipment, net	1,857	2,669
Operating right-of-use assets, net	5,862	0
Intangible assets	11,919	15,393
Total long-term assets	41,370	46,873
TOTAL ASSETS	125,378	157,372
CURRENT LIABILITIES:
Trade payables	8,033	8,418
Accrued expenses and other current liabilities	16,667	19,512
Current portion of long-term debt	7,735	0
Income taxes payable	117	294
Unearned interest income	2,397	2,678
Warranty accrual	1,074	1,245
Deferred revenues	1,765	2,030
Operating lease liabilities	1,807	0
Current portion of government assistance loans	0	543
Total current liabilities	39,595	34,720
LONG-TERM LIABILITIES:
Long-term debt	70,003	77,325
Income tax payable	374	563
Accrued severance pay	867	911
Deferred tax liabilities	0	46
Unearned interest income	957	1,355
Warranty accrual	408	508
Long-term operating lease liabilities	4,221	0
Other long-term liabilities	215	348
Total long-term liabilities	77,045	81,056
TOTAL LIABILITIES	116,640	115,776
Commitments and Contingencies (Note 9)
STOCKHOLDERS’ EQUITY (Note 1):
Common Stock, $0.0001 par value: 300,000,000 shares authorized as of December 31, 2022 and 2021; 77,125,328 and 63,982,580 issued and outstanding as of December 31, 2022 and 2021, respectively	29	27
Additional paid-in capital	232,169	221,321
Accumulated deficit	(224,105)	(180,405)
TOTAL STOCKHOLDERS’ EQUITY	8,093	40,943
Non-controlling interests	645	653
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance	8,738	41,596
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 125,378	$ 157,372

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts receivable, allowance, current	$ 13,619	$ 11,997
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	77,125,328	63,982,580
Common stock, shares outstanding (in shares)	77,125,328	63,982,580

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue
Revenues	$ 99,497	$ 105,622
Cost of goods sold
Cost of goods and services sold	33,526	31,528
Gross profit	65,971	74,094
Operating expenses:
Selling and marketing	40,276	41,920
General and administrative	49,618	40,070
Research and development	10,953	9,646
Total operating expenses	100,847	88,861
Loss from operations	(34,876)	(14,767)
Other expenses:
Foreign exchange loss	3,387	2,559
Finance expenses	4,561	4,955
Loss on disposal of subsidiaries	1,482	567
Loss before income taxes	(44,306)	(22,848)
Income tax (benefit) expense	(722)	(707)
Net loss	(43,584)	(22,141)
Net loss attributable to stockholders of the Company	(43,700)	(23,013)
Net income (loss) attributable to non-controlling interest	$ 116	$ 872
Net loss per share:
Basic (in dollars per share)	$ (0.66)	$ (0.42)
Diluted (in dollars per share)	$ (0.66)	$ (0.42)
Weighted-average number of shares used in per share calculation:
Basic (in shares)	65,960	54,466
Diluted (in shares)	65,960	54,466
Government Assistance Loans [Member]
Operating expenses:
Gain (loss) on debt extinguishment	$ 0	$ (2,775)
Leases [Member]
Revenue
Revenues	35,267	45,094
Cost of goods sold
Cost of goods and services sold	9,435	10,459
Products and Services [Member]
Revenue
Revenues	64,230	60,528
Cost of goods sold
Cost of goods and services sold	$ 24,091	$ 21,069

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Net loss	$ (43,584)	$ (22,141)
Net loss attributable to stockholders of the Company	(43,700)	(23,013)
Income (loss) attributable to non-controlling interest	116	872
Comprehensive loss	$ (43,584)	$ (22,141)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Private Placement [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member] Noncontrolling Interest [Member]	Private Placement [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]		Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Series A Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020							0	53,551,126
Balance at Dec. 31, 2020							$ 0	$ 26		$ 201,598	$ (157,392)	$ (471)		$ 43,761
Issuance of common stock (in shares)	3,790,755	9,808,418
Issuance of common stock	$ 0	$ 1	$ 16,587	$ 0	$ 0	$ 16,588
Dividends from subsidiaries							$ 0	$ 0		0	0	(293)		(293)
December 2020 Public Offering warrants exercise (in shares)							0	361,200
December 2020 Public Offering warrants exercise							$ 0	$ 0		903	0	0		903
Beneficial conversion feature							0	0		152	0	0	$ 152	152
Acquisition of non-controlling interest							0	0		(341)	0	341		0
Net loss — the Company							0	0		0	(23,013)	0		(23,013)
Net loss — non-controlling interest							$ 0	$ 0		0	0	872		872
Options exercised (in shares)							0	261,836
Options exercised							$ 0	$ 0		354	0	0		354
Disposal of subsidiary							0	0		0	0	204		204
Stock-based compensation							$ 0	$ 0		2,068	0	0		2,068
Balance (in shares) at Dec. 31, 2021							3,790,755	63,982,580
Balance at Dec. 31, 2021							$ 0	$ 27		221,321	(180,405)	653		41,596
Issuance of common stock (in shares)	3,185,000	1,750,000					0	7,585,529
Issuance of common stock	$ 0	$ 0	$ 6,518	$ 0	$ 0	$ 6,518	$ 0	$ 1		2,203	0	0		2,204
Dividends from subsidiaries							0	0		0	0	(124)		(124)
Net loss — the Company							0	0		0	(43,700)	0		(43,700)
Net loss — non-controlling interest							$ 0	$ 0		0	0	116		$ 116
Options exercised (in shares)							0	16,464						16,464
Options exercised							$ 0	$ 0	[1]	23	0	0		$ 23
Stock-based compensation							$ 0	$ 0		2,104	0	0		2,104
Conversion of 2021 Private Placemat shares (in shares)							(3,790,755)	3,790,755
Conversion of 2021 Private Placemat shares							$ 0	$ 1		0	0	0		1
Balance (in shares) at Dec. 31, 2022							3,185,000	77,125,328
Balance at Dec. 31, 2022							$ 0	$ 29		$ 232,169	$ (224,105)	$ 645		$ 8,738
[1]Presented as $0 due to rounding.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (43,584)	$ (22,141)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,463	4,854
Stock-based compensation	2,104	2,068
Provision (recovery) for bad debt	7,337	(263)
Provision for inventory obsolescence	2,420	1,456
Finance expenses and accretion	414	1,779
Deferred tax recovery	(709)	(165)
Loss on sale of subsidiaries	0	567
Loss on disposal of property and equipment	158	0
Changes in operating assets and liabilities:
Accounts receivable short- and long-term	9,855	(869)
Inventories	(5,783)	(4,261)
Prepaid expenses	1,049	(454)
Advances to suppliers	(214)	(3,080)
Other current assets	56	1,908
Operating right-of-use assets, net	(5,862)	0
Other long-term assets	200	(98)
Trade payables	(385)	2,096
Accrued expenses and other current liabilities	(3,647)	(889)
Current operating lease liabilities	1,807	0
Severance payments	76	(132)
Unearned interest income	(679)	305
Long-term operating lease liabilities	4,221	0
Other long-term liabilities	(277)	323
Net cash used in operating activities	(26,980)	(19,771)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(336)	(512)
Cash received from sale of subsidiaries, net of cash relinquished	0	(40)
Net cash used in investing activities	(336)	(552)
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercises of 2020 December Public Offering Warrants	0	903
Proceeds from issuance of common stock	2,135	0
Repayment of government assistance loans	(543)	(738)
Dividends from subsidiaries paid to non-controlling interest	(124)	(293)
Payment of earn-out liability	0	(147)
Proceeds from exercise of options	23	354
Net cash provided by financing activities	8,009	16,819
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(19,307)	(3,504)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of year	30,876	34,380
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of year	11,569	30,876
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	329	116
Cash paid for interest	4,147	3,292
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Common stock issuance costs	438	0
The 2021 Private Placement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Private Placement, net of costs	0	16,740
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Private Placement costs	0	259
The 2022 Private Placement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Private Placement, net of costs	6,518	0
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Private Placement costs	202	0
Government Assistance Loans [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Gain (loss) on debt extinguishment	$ 0	$ (2,775)

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Stock issuance costs		$ 202
The 2022 Private Placement [Member]
Stock issuance costs	$ 202		$ 259

Note 1 - Nature of Operations

Note 1 - Nature of Operations	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Nature of Operations [Text Block]	1. Venus Concept Inc. is a global medical technology company that develops, commercializes, and sells minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The Company’s systems have been designed on cost-effective, proprietary and flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. The Company was incorporated in the state of Delaware on November 22, 2002. Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future, and, as such, the consolidated financial statements do not The Company has had recurring net operating losses and negative cash flows from operations. As of December 31, 2022 December 31, 2021, December 31, 2022, December 31, 2021. 12 December 31, 2022, twelve 19 19 In order to continue its operations, the Company must achieve profitable operations and/or obtain additional equity or debt financing. Until the Company achieves profitability, management plans to fund its operations and capital expenditures with cash on hand, borrowings, and issuance of capital stock. On June 16, 2020, may two December 31, 2022, July 1, 2022. July 12, 2022, 2022 16 December 2021, 2021 16 February 2021, December 2020 December 2020 November 2022, 2022 16 Given the economic uncertainty in U.S. and international markets, the Company cannot anticipate the extent to which the current economic turmoil and financial market conditions will continue to adversely impact the Company’s business and the Company may no may not The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future, and, as such, the consolidated financial statements do not Operational Review of Subsidiaries During the year ended December 31, 2022, not November 2022, no December 31, 2022. not not 205 20 45.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and with the instructions to Form 10 X. The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company as of December 31, 2022 not Amounts reported in thousands within this report are computed based on the amounts in dollars. As a result, the sum of the components reported in thousands may not may not In the Form 10 March 31, 2021, May 17, 2021, 10 June 30, 2021, August 17, 2021, 10 September 30, 2021, November 12, 2021 10 December 31, 2021, March 28, 2022, 18 Reclassification Adjustment Three Months Ended Year Ended March 31, 2021 June 30, 2021 September 30, 2021 December 31, 2021 December 31, 2021 United States $ (362 ) $ (615 ) $ (703 ) $ (440 ) $ (2,120 ) International 362 615 703 440 2,120 Total revenue $ — $ — $ — $ — $ — Additionally, the Company performed reclassifications within the Operating Expenses section of the Statements of Operations. The intent was to reclassify clinical affairs costs and clinical training costs previously presented within general and administrative expenses into research and development and selling and marketing expenses, respectively. The following table summarizes the impact of the reclassification adjustment on the Company's Annual Report on Form 10 March 28, 2022, 10 2021 2022: As previously reported Adjustment As reclassified Consolidated statements of operations: For the year ended December 31, 2021 Selling and marketing $ 37,438 $ 4,482 $ 41,920 General and administrative 45,940 (5,870 ) 40,070 Research and development 8,258 1,388 9,646 Condensed consolidated statements of operations for the three months ended: March 31, 2022 Selling and marketing 9,903 1,181 11,084 General and administrative 13,094 (1,622 ) 11,472 Research and development 2,202 441 2,643 March 31, 2021 Selling and marketing 7,854 1,052 8,906 General and administrative 12,165 (1,408 ) 10,757 Research and development 2,051 356 2,407 June 30, 2022 Selling and marketing 9,487 1,036 10,523 General and administrative 14,249 (1,312 ) 12,937 Research and development 2,436 276 2,712 June 30, 2021 Selling and marketing 10,114 1,139 11,253 General and administrative 7,828 (1,468 ) 6,360 Research and development 2,024 329 2,353 September 30, 2022 Selling and marketing 8,094 1,275 9,369 General and administrative 14,128 (1,723 ) 12,405 Research and development 2,576 448 3,024 September 30, 2021 Selling and marketing 8,775 1,035 9,810 General and administrative 11,990 (1,337 ) 10,653 Research and development 1,930 302 2,232 Reclassification of Comparative Amounts The Company previously offset certain Trade Payables with Advances to Suppliers associated with one no not The following table summarizes the impact of the reclassification adjustments on the Company's Form 10 March 28, 2022 2022: As previously reported Adjustment As reclassified Consolidated balance sheets: December 31, 2021 Advances to suppliers $ 2,162 $ 3,505 $ 5,667 Trade payables 4,913 3,505 8,418 March 31, 2022 Advances to suppliers 3,532 2,856 6,388 Trade payables 4,788 2,856 7,644 June 30, 2022 Advances to suppliers 2,869 3,090 5,959 Trade payables 4,184 3,090 7,274 September 30, 2022 Advances to suppliers 3,605 2,186 5,791 Trade payables 6,093 2,186 8,279 The following table summarizes the impact of the reclassification adjustments on the Company's Form 10 March 28, 2022 2022: As previously reported Adjustment As reclassified Consolidated statements of cash flows: For the year ended December 31, 2021 Changes in operating assets and liabilities: Advances to suppliers $ 425 $ (3,505 ) $ (3,080 ) Trade payables (1,409 ) 3,505 2,096 For the three months ended March 31, 2022 Changes in operating assets and liabilities: Advances to suppliers (1,370 ) (2,856 ) (4,226 ) Trade payables (125 ) 2,856 2,731 For the three months ended March 31, 2021 Changes in operating assets and liabilities: Advances to suppliers (1,417 ) (1,680 ) (3,097 ) Trade payables (178 ) 1,680 1,502 For the six months ended June 30, 2022 Changes in operating assets and liabilities: Advances to suppliers (707 ) (3,090 ) (3,797 ) Trade payables (729 ) 3,090 2,361 For the six months ended June 30, 2021 Changes in operating assets and liabilities: Advances to suppliers (772 ) (2,291 ) (3,063 ) Trade payables (640 ) 2,291 1,651 For the nine months ended September 30, 2022 Changes in operating assets and liabilities: Advances to suppliers (1,443 ) (2,186 ) (3,629 ) Trade payables 1,180 2,186 3,366 For the nine months ended September 30, 2021 Changes in operating assets and liabilities: Advances to suppliers (142 ) (2,500 ) (2,642 ) Trade payables (1,573 ) 2,500 927 Principles of Consolidation The accompanying consolidated financial statements include the accounts of Venus Concept Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated on consolidation. Where the Company does not 100% Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not Foreign Currency The consolidated financial statements are presented in U.S. dollars. Amounts reported in thousands within this report are computed based on the amounts in dollars. As a result, the sum of the components reported in thousands may not may not All exchange gains and losses from remeasurement of monetary balance sheet items resulting from transactions in non-functional currencies are recorded in the consolidated statements of operations as they arise. In respect of transactions denominated in currencies other than the Company and its subsidiaries’ functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are remeasured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these transactions are recognized in the consolidated statements of operations. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, accounts receivable and long-term receivables. The Company’s cash and cash equivalents are invested primarily in deposits with major banks worldwide, as such minimal credit risk exists with respect to such investments. The Company’s trade receivables are derived from global sales to customers. An allowance for doubtful accounts is provided with respect to all balances for which collection is deemed to be doubtful. Risks and Uncertainties While the impact of COVID- 19 19 Besides COVID- 19, not may may The Company has borrowings with interest rates that are subject to fluctuations as charged by the lender. The Company does not December 31, 2022 2021 Concentration of Customers For the years ended December 31, 2022 2021 10% 10% Allowance for Doubtful Accounts Trade accounts receivable do not not may December 31, 2022 2021 Inventory Inventories are stated at the lower of cost or net realizable value and include raw materials, work in progress and finished goods. Cost is determined as follows: Raw Materials and Work in Progress (“WIP”) – Cost is determined on a standard cost basis utilizing the weighted average cost of historical purchases, which approximates actual cost. The cost of WIP and finished goods includes the cost of raw materials and the applicable share of the cost of labor and fixed and variable production overheads. The Company regularly evaluates the value of inventory based on a combination of factors including the following: historical usage rates, product end of life dates, technological obsolescence and product introductions. The Company includes demonstration units within inventories. Proceeds from the sale of demonstration units are recorded as revenue. Long-term Receivables Long-term receivables relate to the Company’s subscription revenue or contracts which stipulate payment terms which exceed one December 31, 2022 December 31, 2021. Deferred revenues represent payments received prior to the income being earned. Once the equipment has been delivered or the services have been rendered, these amounts are recognized in income. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is between three ten Leases The Company determines if an agreement is, or contains, a lease at inception. An agreement is, or contains, a lease if the contact conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company leases assets including land and buildings, vehicles, and equipment. For leases with a term of 12 The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. An operating lease is a lease in which a lessor transfers the use of an asset to a lessee for a period of time but does not five i. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. ii. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. iii. The lease term is for a major part (generally 75% iv. The sum of the lease payments and the present value of any residual value guaranteed by the lessee amounts to or exceeds substantially all (generally 90% v. The underlying asset is of such a specialized nature that it is expected to have no For a finance lease, the right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. For an operating lease, amortization of the right-of-use asset is calculated as the difference between the straight-line rent expense and the interest expense on the lease liability for a given period. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability. The lease liability is initially measured at the present value of the lease payments that are not no The lease liabilities are subsequently measured at amortized cost using the effective interest method. They are remeasured when there is a change in future lease payments arising from a change in the lease term, if there is a change in the Company’s estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option. All of our leases for which we are the lessee are operating leases and are included within operating lease right-of-use assets, net, operating lease liabilities, and long-term operating lease liabilities in our Consolidated Balance Sheets. Intangible Assets Intangible assets consist of customer relationships, brand, technology and supplier agreement. Intangible assets are stated at cost less accumulated amortization. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which range from approximately six fifteen The useful lives of intangible assets are based on the Company’s assessment of various factors impacting estimated cash flows, such as the product’s position in its lifecycle, the existence or absence of like products in the market, various other competitive and regulatory issues, and contractual terms. Impairment of Long-Lived Assets The Company accounts for the impairment of long-lived assets in accordance with FASB, ASC 360 10, may not December 31, 2022 2021 Debt Issuance Costs Costs related to the issuance of debt are presented as a direct deduction to the carrying value of the debt and are amortized to accretion expenses using the effective interest rate method over the term of the related debt. Derivatives The Company reviews the terms of convertible notes, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Derivative financial instruments are initially measured at their fair value. Derivative financial instruments that are accounted for as liabilities, are initially recorded at fair value and then re-valued at each reporting date, with changes in the fair value recognized in the consolidated statements of operations. Revenue Recognition The Company adopted ASC 606 606” January 1, 2019 not 606 The Company generates revenue from ( 1 2 3 fourth 2021. Many of the Company’s products are sold under subscription contracts with control passing to the customer at the earlier of the end of the term and when the payment is received in full. The subscription contracts include an initial deposit followed by monthly installments typically over a period of 36 months. In accordance with ASC 840 840” The Company recognizes revenues on other products and services in accordance with ASC 606. five 1 2 3 4 5 The Company does not Cost of Goods For subscription sales (qualifying as sales-type lease arrangements) and product sales, the costs are recognized upon shipment to the customer or distributor. Advertising Costs The cost of advertising and media is expensed as incurred. For the years ended December 31, 2022 2021 Research and Development Research and development costs are charged to operations as incurred. Major components of research and development expenses consist of personnel costs, including salaries and benefits, hardware and software research and development costs, and clinical studies. Warranty The Company provides a standard warranty against defects for all of its systems. The warranty period begins upon shipment and is for a period of one three The Company records a liability for accrued warranty costs at the time of sale of a system, which consists of the warranty on products sold based on historical warranty costs and management’s estimates. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts thereof as necessary. The Company also provides an extended warranty service. Extended warranty can be purchased at any time after the purchase of a system and prior to the expiration of the standard warranty provided with the sale of the system. Extended warranty services include standard warranty services. The Company recognizes the revenue from the sale of an extended warranty over the period of the extended warranty and accounts it for separately from the standard warranty. Income Taxes The Company follows the deferred income taxes method of accounting for income taxes. Under this method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying values of accounts and their respective income tax basis. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years during which the temporary differences are expected to be realized or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is included in income in the period that includes the enactment date. The Company establishes valuation allowances when necessary to reduce deferred tax assets to the amounts that are more likely than not not” not not” not Uncertain Tax Positions The Company recognizes the effect of income tax positions only if those positions are more likely than not first not second 50% The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, 718” 718 The fair value of stock options (“options”) on the grant date is estimated using the Black-Scholes option-pricing model using the single-option approach. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions, including the option’s expected term and the price volatility of the underlying stock, to determine the fair value of the award. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. The Company has made a policy choice to account for forfeitures when they occur. Net Loss Per Share The Company computes net (loss) income per share in accordance with ASC Topic 260, 260” two two not Diluted net (loss) income per share is the same as basic net (loss) income per share for the periods in which the Company had a net loss because the inclusion of outstanding common stock equivalents would be anti-dilutive. Recently Adopted Accounting Standards In November 2021, No. 2021 10, 832 December 31, 2021. 14 In February 2016, No. 2016 02 842 2016 02” On January 1, 2022, not The Company elected the optional package of practical expedients to not not As a result of the adoption of ASU 2016 02, no Operating lease ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. Upon adoption of ASU 2016 02, January 1, 2022. 2016 02, January 1, 2022. All real estate leases are recorded on the balance sheet. Equipment and other non-real estate leases with an initial term of twelve not one not may no not The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgment to determine if an asset is specified in the contract and if the Company directs how and for what purpose the asset is used during the term of the contract. In October 2021, No. 2021 08, 805 606, December 15, 2022, not In May 2021, 2021 04, 260 470 50 718 815 40 1 2 December 15, 2021, not In March 2020, 2020 04 848 2021, March 12, 2020 December 31, 2022. may no December 31, 2022. January 2021, may 848. not In December 2019, 2019 12 740 first 2022, not Recently Issued Accounting Standards Not Yet Adopted In August 2020, No. 2020 06 2020 06” 470 20 815 40 2020 06 2020 06 January 1, 2024, No. 2020 06 In February 2020, 2020 02 326 842 326 842. 326, 326 January 1, 2023,

Note 3 - Net Loss Per Share

Note 3 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	3. Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock warrants and stock options are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share (in thousands, except per share data): For the year ended December 31, 2022 2021 Numerator: Net loss $ (43,584 ) $ (22,141 ) Net loss allocated to stockholders of the Company $ (43,700 ) $ (23,013 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share, basic and diluted 65,960 54,466 Net loss per share: Basic and diluted $ (0.66 ) $ (0.42 ) Due to the net loss, all the outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2022 2021 December 31, 2022 2021 Options to purchase common stock and restricted stock units ("RSUs") 12,741,394 5,977,179 Preferred stock 31,850,000 3,790,755 Restricted Stock 388,750 - Shares reserved for convertible notes 8,215,706 8,213,880 Warrants for common stock 15,928,867 15,928,867 Total potential dilutive shares 69,124,717 33,910,681

Note 4 - Sale of Subsidiaries

Note 4 - Sale of Subsidiaries	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	4. Beginning in 2020, not December 31, 2021, • Sold its share (80%) in its subsidiary, Venus Concept Africa (Pty) Ltd., to a non-controlling shareholder for a nominal cash consideration. The disposal resulted in a loss of approximately $188 for the year ended December 31, 2021, December 31, 2022. • In 2020, third 2021 • Filed a Certificate of Dissolution to dissolve its wholly-owned subsidiary, Restoration Robotics Spain S.L. The dissolution resulted in no December 31, 2021. As a part of this initiative over the course of fiscal year ended December 31, 2022, • Filed a Certificate of Dissolution to dissolve its wholly-owned subsidiary, Venus France. The dissolution resulted in a loss of approximately $60 for the year ended December 31, 2022. As these disposals did not not not 205 20 45. In addition to the above, on September 7, 2021,

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	5. Financial assets and financial liabilities are initially recognized at fair value when the Company becomes a party to the contractual provisions of the financial instrument. Subsequently, all financial instruments are measured at amortized cost using the effective interest method. The financial instruments of the Company consist of cash and cash equivalents, restricted cash, accounts receivable, long-term receivables, lines of credit, trade payables, government assistance loans, accrued expenses and other current liabilities, other long-term liabilities and long-term debt. In view of their nature, the fair value of these financial instruments approximates their carrying amounts. The Company measures the fair value of its financial assets and financial liabilities using the fair value hierarchy. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The accounting guidance establishes a three Level 1 Level 2 1 not Level 3 no Guaranteed investment certificates are classified within Level 2 3. 1, 2 3 Fair Value Measurements as of December 31, 2022 Quoted Prices in Active Markets using Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Guaranteed Investment Certificates $ — $ 59 $ — $ 59 Total assets $ — $ 59 $ — $ 59 Fair Value Measurements as of December 31, 2021 Quoted Prices in Active Markets using Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Guaranteed Investment Certificates $ — $ 64 $ — $ 64 Total assets $ — $ 64 $ — $ 64

Note 6 - Accounts Receivable

Note 6 - Accounts Receivable	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Trade and Financing Receivables [Text Block]	6. The Company’s products may A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset on the Company’s consolidated balance sheets. The Company’s financing receivables, consisting of its sales-type leases, totale d $40,377 December 31, 2022 2021 T he Company performed an assessment of the allowance for doubtful accounts as of December 31, 2022 2021 . Based upon such assessment, the Company recorded an allowance for doubtful totaling $13,619 and $11,997 as of December 31, 2022 2021 , respectively. A summary of the Company’s accounts receivables is presented as follows: As of December 31, 2022 2021 Gross accounts receivable $ 70,925 $ 86,625 Unearned income (3,354 ) (4,033 ) Allowance for doubtful accounts (13,619 ) (11,997 ) $ 53,952 $ 70,595 Reported as: Current trade receivables $ 37,262 $ 46,918 Current unearned interest income (2,397 ) (2,678 ) Long-term trade receivables 20,044 27,710 Long-term unearned interest income (957 ) (1,355 ) $ 53,952 $ 70,595 Current subscription contracts are reported as part of accounts receivable. The following are the contractual commitments, net of allowance for doubtful accounts, to be received by the Company over the next 5 December 31, Total 2023 2024 2025 2026 2027 Current financing receivables, net of allowance of $ 6,938 $ 20,333 $ 20,333 $ — $ — $ — $ — Long-term financing receivables, net of allowance of $ 906 20,044 — 15,965 4,029 50 — $ 40,377 $ 20,333 $ 15,965 $ 4,029 $ 50 $ — Accounts receivable do not not may The allowance for doubtful accounts consisted of the following activity for years ended December 31, 2022 2021: As of December 31, 2022 2021 Balance at beginning of year $ 11,997 $ 18,490 Write-offs (5,715 ) (6,230 ) (Recovery) provision 7,337 (263 ) Balance at end of year $ 13,619 $ 11,997

Note 7 - Select Balance Sheet a

Note 7 - Select Balance Sheet and Statement of Operations Information	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Balance Sheet and Income Statement Disclosures [Text Block]	7. Inventory Inventory consists of the following: December 31, 2022 2021 Raw materials $ 2,478 $ 2,368 Work-in-progress 2,112 1,649 Finished goods 19,316 16,526 Total inventory $ 23,906 $ 20,543 Additions to inventory are primarily comprised of newly produced units and applicators, refurbishment cost from demonstration units and used equipment which were reacquired during the year from upgraded sales. The Company expensed $31,555 2021 The Company provides for excess and obsolete inventories when conditions indicate that the inventory cost is not December 31, 2022 2021 Property and Equipment, Net Property and equipment, net consist of the following: December 31, Useful Lives (in years) 2022 2021 Lab equipment tooling and molds 4 – 10 $ 4,356 $ 8,194 Office furniture and equipment 6 – 10 1,240 1,743 Leasehold improvements up to 10 794 1,839 Computers and software 3 906 1,939 Vehicles 5 – 7 37 37 Demo units 5 214 114 Total property and equipment 7,547 13,866 Less: Accumulated depreciation (5,690 ) (11,197 ) Total property and equipment, net $ 1,857 $ 2,669 Depreciation expense amounted to $990 December 31, 2022 2021 Other Current Assets December 31, 2022 2021 Government remittances (1) $ 1,602 $ 1,322 Consideration receivable from subsidiaries sale 629 1,405 Deferred financing costs 301 223 Sundry assets and miscellaneous 1,170 808 Total other current assets $ 3,702 $ 3,758 ( 1 Government remittances are receivables from the local tax authorities for refund of sales taxes and income taxes. Accrued Expenses and Other Current Liabilities December 31, 2022 2021 Payroll and related expense $ 2,244 $ 1,770 Accrued expenses 5,045 6,584 Commission accrual 3,761 4,529 Sales and consumption taxes 5,617 6,629 Total accrued expenses and other current liabilities $ 16,667 $ 19,512 Warranty Accrual The following table provides the details of the change in the Company’s warranty accrual: December 31, 2022 2021 Balance as of the beginning of the year $ 1,753 $ 1,639 Warranties issued during the year 993 1,231 Warranty costs incurred during the year (1,264 ) (1,117 ) Balance at the end of the year $ 1,482 $ 1,753 Current 1,074 1,245 Long-term 408 508 Total $ 1,482 $ 1,753 Finance Expenses The following table provides the details of the Company’s finance expenses: December 31, 2022 2021 Interest expense $ 4,297 $ 3,720 Accretion on long-term debt and amortization of fees 264 1,235 Total finance expenses $ 4,561 $ 4,955

Note 8 - Leases

Note 8 - Leases	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. The following presents the various components of lease costs. Year Ended December 31, 2022 Operating lease cost $ 1,942,765 Short-term lease cost 267,503 Total lease cost $ 2,210,268 The following table presents supplemental information relating to the cash flows arising from lease transactions. Cash payments related to short-term leases are not Year Ended December 31, 2022 Operating cash outflows from operating leases $ 1,943 The following table presents the weighted-average lease term and discount rate for operating leases. Year Ended December 31, 2022 Operating leases Weighted-average remaining lease term 4.2 yrs. Weighted-average discount rate 4.00 % The following table presents a maturity analysis of expected undiscounted cash flows for operating leases on an annual basis for the next five Years ending December 31, Operating leases 2023 $ 1,807 2024 1,409 2025 1,228 2026 1,038 2027 594 Thereafter 544 Imputed Interest (1) (592 ) Total $ 6,028 ( 1 Imputed interest represents the difference between undiscounted cash flows and cash flows.

Note 9 - Intangible Assets and

Note 9 - Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	9. In November 2019, The carrying values of goodwill and indefinite-life intangible assets are subject to annual impairment assessment as of the last day of each fiscal year. Between annual assessments, impairment review may December 31, 2022 2021 Intangible assets net of accumulated amortization were as follows: At December 31, 2022 Gross Amount Accumulated Amortization Net Amount Customer relationships $ 1,400 $ (429 ) $ 971 Brand 2,500 (1,066 ) 1,434 Technology 16,900 (8,919 ) 7,981 Supplier agreement 3,000 (1,467 ) 1,533 Total intangible assets $ 23,800 $ (11,881 ) $ 11,919 At December 31, 2021 Gross Amount Accumulated Amortization Net Amount Customer relationships $ 1,400 $ (336 ) $ 1,064 Brand 2,500 (803 ) 1,697 Technology 16,900 (6,103 ) 10,797 Supplier agreement 3,000 (1,165 ) 1,835 Total intangible assets $ 23,800 $ (8,407 ) $ 15,393 Amortization expense was $3,473 for the years ended December 31, 2022 2021. Estimated amortization expense for the next five Years ending December 31, 2023 $ 3,473 2024 3,473 2025 3,004 2026 657 2027 657 Thereafter 655 Total $ 11,919

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments As of December 31, 2022 mount of $20,775 December 31, 2022 of open purchase orders that can be cancelled with 270 On March 25, 2021, four seven November 1, 2022. Aggregate service and purchase commitments with manufacturers as of December 31, 2022 Years ending December 31, Purchase and Service Commitments 2023 $ 21,174,831 2024 — 2025 — 2026 — 2027 — Thereafter — Total $ 21,174,831 Legal Proceedings Purported Shareholder Class Actions In 2018 2019, four No. 18CIV02609, No. 19CIV08173 11, 12 2 15 No. 5:18 03712 No. 5:18 03883 11 15 September 1, 2017 October 13, 2017 not September 9, 2021. February 16, 2023, February 17, 2023. In the State Actions, the Plaintiffs filed a consolidated amended complaint on January 17, 2020 March 30, 2020, September 1, 2020 September 22, 2020. November 23, 2020, April 20, 2022, April 28, 2022, June 7, 2022, June 27, 2022, July 7, 2022. July 27, 2022, October 25, 2022, no On July 11, 2019, No. 5:19 03997 14 2018 August 21, 2019, June 21, 2021, March 2, 2023, not

Note 11 - Main Street Term Loan

Note 11 - Main Street Term Loan	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	11. On December 8, 2020, December 9, 2020, five 30 December 8, 2023 December 8, 2024, fifteen December 8, 2025. may As of December 31, 2022 December 31, 2021, The scheduled payments on the outstanding borrowings as of December 31, 2022 As of December 31, 2022 2023 $ 11,594 2024 9,870 2025 40,053 Total $ 61,517

Note 12 - Madryn Long-term Debt

Note 12 - Madryn Long-term Debt and Convertible Notes	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	11. On December 8, 2020, December 9, 2020, five 30 December 8, 2023 December 8, 2024, fifteen December 8, 2025. may As of December 31, 2022 December 31, 2021, The scheduled payments on the outstanding borrowings as of December 31, 2022 As of December 31, 2022 2023 $ 11,594 2024 9,870 2025 40,053 Total $ 61,517
Madryn Long Term Debt and Convertible Notes [Member]
Notes to Financial Statements
Debt Disclosure [Text Block]	12. On October 11, 2016, four September 30, 2020, 1 2 24th September 30, 2022, December 9, 2020 On December 9, 2020, 11 December 8, 2020, December 9, 2020 The Notes will accrue interest at a rate of 8.0% per annum from the date of original issuance of the Notes to the third December 31, 2020. December 9, 2025 first not 11 13 December 31, 2022 December 31, 2021, 815 10 15 not 815, two December 31, 2022, December 31, 2021, December 31, 2022, December 31, 2021. The scheduled payments on the outstanding borrowings as of December 31, 2022 As of December 31, 2022 2023 $ 2,137 2024 1,628 2025 28,217 Total $ 31,982 For the years ended December 31, 2022 2021, not

Note 13 - Credit Facility

Note 13 - Credit Facility	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Credit Facility Disclosure [Text Block]	13. CREDIT FACILITY On August 29, 2018, March 20, 2020, December 9, 2020 August 26, 2021 ( August 29, 2018, March 20, 2020, December 9, 2020 August 26, 2021 ( March 20, 2020, December 9, 2020 August 26, 2021, The CNB Loan Agreement contains various covenants that limit the Company’s ability to engage in specified types of transactions. Subject to limited exceptions, these covenants limit the Company’s ability, without CNB’s consent, to, among other things, sell, lease, transfer, exclusively license or dispose of the Company’s assets, incur, create or permit to exist additional indebtedness, or liens, to make dividends and certain other restricted payments, and to make certain changes to its management and/or ownership structure. The Company is required to maintain $3,000 in cash in a deposit account maintained with CNB at all times during the term of the CNB Loan Agreement. In addition, the CNB Loan Agreement contains certain covenants that require the Company to achieve certain minimum account balances, or a minimum debt service coverage ratio and a maximum total liability to tangible net worth ratio. If the Company fails to comply with these covenants, it will result in a default and require the Company to repay all outstanding principal amounts and any accrued interest. In connection with the CNB Loan Agreement, a loan fee of $1,000 was paid in equal installments on January 25, February 25 March 25, 2021. On August 26, 2021, 30 December 10, 2021, As of December 31, 2022 December 31, 2021 r the MSLP Loan (see Note 11 In connection with the Amended CNB Loan Agreement, the Company, Venus USA and Venus Canada issued a promissory note dated August 26, 2021, July 24, 2023 August 26, 2021 ( February 22, 2023, 2

Note 14 - Government Assistance

Note 14 - Government Assistance Programs	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Government Assistance Programs [Text Block]	14. Venus Concept Inc. and Venus USA, received funding in the total amount of $4,048 in connection with two 7 1953, Venus Concept Inc. entered into a U.S. Small Business Administration Note dated as of April 21, 2020 April 29, 2020 ( 1% two Venus USA entered into a U.S. Small Business Administration Note dated as of April 15, 2020 April 20, 2020 ( The Venus Concept PPP Loan contained certain covenants which, among other things, restrict the Company’s use of the proceeds of the PPP Loan to the payment of payroll costs, interest on mortgage obligations, rent obligations and utility expenses, require compliance with all other loans or other agreements with any creditor of the Company, to the extent that a default under any loan or other agreement would materially affect the Company’s ability to repay its PPP Loan and limit the Company’s ability to make certain changes to its ownership structure. In 2021, three March 31, 2022, April 2022. December 31, 2022 $nil December 31, 2021).

Note 15 - Common Stock Reserved

Note 15 - Common Stock Reserved for Issuance	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Common Stock Reserved For Issuance [Text Block]	15. The Company is required to reserve and keep available out of its authorized but unissued shares of common stock a number of shares sufficient to affect the exercise of all options granted and available for grant under the incentive plans and warrants to purchase common stock. December 31, 2022 December 31, 2021 Outstanding common stock warrants 15,928,867 15,928,867 Outstanding stock options and RSUs 13,130,144 5,977,179 Preferred shares 31,850,000 3,790,755 Shares reserved for conversion of future non-voting preferred share issuance 1,209,245 1,209,245 Shares reserved for conversion of future voting preferred share issuance 9,150,000 — Shares reserved for future option grants and RSUs 376,201 589,064 Shares reserved for Lincoln Park 15,814,471 5,222,867 Shares reserved for Madryn Noteholders 8,215,706 8,213,880 Total common stock reserved for issuance 95,674,634 40,931,857

Note 16 - Stockholders Equity

Note 16 - Stockholders Equity	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	16. Common Stock The Company’s common stock confers upon its holders the following rights: • The right to participate and vote in the Company’s stockholder meetings, whether annual or special. Each share will entitle its holder, when attending and participating in the voting in person or via proxy, to one • The right to a share in the distribution of dividends, whether in cash or in the form of bonus shares, the distribution of assets or any other distribution pro rata to the par value of the shares held by them; and • The right to a share in the distribution of the Company’s excess assets upon liquidation pro rata to the par value of the shares held by them. Equity Purchase Agreement with Lincoln Park On June 16, 2020, may may no no 5635 no may From commencement to expiry on July 1, 2022, 2022, December 31, 2022 July 1, 2022, 2022 2022 LPC Purchase Agreement with Lincoln Park On July 12, 2022, 2022 July 1, 2022. 2022 may 2022 “2022 2022 2022 may not 2022 “2022 2022 2022 no 2022 2022 five 2022 2022 2022 2022 may not 2022 2022 2022 December 31, 2022, 2022 8 July 12, 2022. The 2021 Private Placement In December 2021, 2021 “2021 2021 2021 2021 December 15, 2021. 2021 2021 2021 2021 10 March 28, 2022. Preferred Stock issued in December 2021 As noted above, in December 2021, 2021 December 14, 2021. • Voting Rights. no • Liquidation. not • Conversion . 1:1, not 2022 • Dividends. • Redemption not • Maturity. Upon issuance, the effective conversion price of the Non-Voting Preferred Stock of $1.25 per share was lower than the market price of the Company’s common stock on the date of issuance of the Non-Voting Preferred Stock of $1.29 per share; as a result, the Company recorded the beneficial conversion feature of $152 in accumulated paid in capital ("APIC"). Because the Non-Voting Preferred Stock is perpetual, it is carried at the amount recorded at inception. Upon conversion of the Non-Voting Preferred Stock, the beneficial conversion feature will be accounted for as deemed dividend. The Company evaluated the Non-Voting Preferred Stock for liability or equity classification in accordance with the provisions of ASC 480, not not not not 480 Since the Non-Voting Preferred Stock was sold as a unit with the common stock, the proceeds received were allocated to each instrument on a relative fair value basis. Total net proceeds of $16,740 reduced by $152 of the beneficial conversion feature were allocated as follows: $4,514 to the Non-Voting Preferred Stock and $12,074 to shares of common stock. The Non-Voting Preferred Stock and common stock issued in the 2021 The 2022 Private Placement In November 2022, 2022 “2022 2022 30 2022 November 18, 2022. 2022 2022 2022 2022 8 November 18, 2022. Voting Preferred Stock issued in November 2022 As noted above, in November 2022, 2022 November 17, 2022. • Voting Rights. • Liquidation. • Conversion one 30 30 two • Dividends. • Redemption not • Maturity. 2010 In November 2010, “2010 2010 seven ten November 2017 2010 not December 31, 2022 December 31, 2021 2010 December 31, 2021 2019 Incentive Award Plan The 2019 “2019 2017 September 12, 2017 September 14, 2017. 2017 October 4, 2019. Under the 2019 2019 December 31, 2022 2019 December 31, 2021 2019 first 2020 2029 four The Company recognized stock-based compensation for its employees and non-employees in the accompanying consolidated statements of operations as follows: Year Ended December 31, 2022 2021 Cost of sales $ 73 $ 31 Selling and marketing 576 848 General and administrative 1,195 1,084 Research and development 260 105 Total stock-based compensation $ 2,104 $ 2,068 Stock Options The fair value of each option is estimated at the date of grant using the Black-Scholes option pricing formula with the following assumptions : Year Ended December 31, 2022 2021 Expected term (in years) 6.00 6.00 Risk-free interest rate 2.56-4.20 % 0.98-1.36 % Expected volatility 42.77 % 44.26 % Expected dividend rate 0 % 0 % Expected Term Volatility not Risk-Free Interest Rate zero Dividend Rate not Fair Value of Common Stock The following table summarizes stock option activity under the Company’s stock option plan: Number of Shares Weighted- Average Exercise Price per Share, $ Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding – January 1, 2022 5,977,179 $ 3.72 7.20 $ 136 Options granted 8,238,250 0.62 209 Options exercised (16,464 ) 1.59 - Options forfeited/cancelled (1,457,571 ) 4.15 — — Outstanding - December 31, 2022 12,741,394 $ 1.67 8.23 $ 209 Exercisable – December 31, 2022 3,376,223 $ 3.78 5.41 $ — Expected to vest – after December 31, 2022 9,365,171 $ 0.91 9.24 $ 209 The following tables summarize information about share options outstanding and exercisable on December 31, 2022 Options Outstanding Options Exercisable Exercise Price Range Number Weighted average remaining contractual term (years) Weighted average Exercise Price Options exercisable Weighted average remaining contractual term (years) Weighted average Exercise Price $0.21 - $3.64 11,915,903 8.47 $ 1.26 2,586,015 5.64 $ 2.58 $4.26 - $7.95 783,523 4.71 6.68 748,243 4.62 6.70 $12.45 - $25.50 24,277 5.75 18.06 24,274 5.75 18.06 $27.00 - $29.25 9,752 2.30 27.01 9,752 2.30 27.01 $36.00 - $63.90 7,939 4.90 45.65 7,939 4.90 45.65 12,741,394 8.23 $ 1.67 3,376,223 5.41 $ 3.78 The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. The total intrinsic value of options exercised were $0 and $92 for the years ended December 31, 2022 2021 The weighted-average grant date fair value of options granted was $0.62 and $2.20 per share for the years ended December 31, 2022 2021 December 31, 2022 2021, Restricted Stock Units The following table summarizes information about RSUs outstanding at December 31, 2022: Number of Shares Weighted- Average Grant Date Fair Value per Share, $ Outstanding - January 1, 2022 — $ — RSUs granted 396,250 1.30 RSUs forfeited/cancelled (7,500 ) 1.38 Outstanding - December 31, 2022 388,750 $ 1.30

Note 17 - Income Taxes

Note 17 - Income Taxes	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	17. The geographical breakdown of loss before provision for income taxes is as follows: Year Ended December 31, 2022 2021 United States $ (32,045 ) $ (12,260 ) Other jurisdictions (12,261 ) (10,588 ) Loss before income taxes $ (44,306 ) $ (22,848 ) The components of the provision for income taxes are as follows: Year Ended December 31, 2022 2021 Current tax provision (benefit): Federal $ — $ — Foreign (13 ) (542 ) Total current tax provision (benefit) (13 ) (542 ) Deferred tax provision (benefit): Federal — — Foreign (709 ) (165 ) Total deferred tax provision (benefit) $ (709 ) $ (165 ) Total provision (benefit) for income taxes $ (722 ) $ (707 ) Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided when it is more likely than not not December 31, 2022 December 31, 2021) not no December 31, 2022 2021 The Company’s effective tax rate substantially differed from the federal statutory tax rate primarily due to the change in the valuation allowance. The reconciliation between income taxes computed at the federal statutory income tax rate and the provision for income taxes is as follows: Year Ended December 31, 2022 2021 Loss before income taxes $ (44,306 ) $ (22,848 ) Theoretical tax benefit at the statutory rate ( 21.0 (9,304 ) (4,798 ) Differences in jurisdictional tax rates (1,671 ) (350 ) Valuation allowance 10,015 5,755 Non-deductible expenses 803 (266 ) Other (565 ) (1,048 ) Total income tax (benefit) provision (722 ) (707 ) Net loss $ (43,584 ) $ (22,141 ) The components of the deferred tax assets and deferred tax liabilities are as follows: December 31, 2022 2021 Deferred tax assets: Property and equipment $ 690 $ 668 Deferred revenue 1,560 647 Allowance for doubtful accounts 3,917 3,133 Intangible assets (785 ) (1,543 ) Non-deductible expenses 10,371 8,694 Warranty and other reserves 1,806 1,159 Other 1,020 610 Loss carryforwards 46,709 38,353 Valuation allowance (64,341 ) (51,437 ) Total deferred tax assets $ 947 $ 284 Deferred tax liabilities: Deferred revenue $ — $ 46 Total deferred tax liabilities $ — $ 46 As of December 31, 2022 2021 not 2022 nil December 31, 2022 2025 not no The Company may not 50% 740 Utilization of the research and development credits carryforwards may not may The Company files income tax returns in the United States and in various state jurisdictions with varying statutes of limitations. Tax years 2016 2022 Uncertain Tax Positions The activity related to gross amount of unrecognized tax benefits is as follows: Year Ended December 31, 2022 2021 Balance as of the beginning of the year $ 36 $ 1,584 Increases (reductions) related to tax positions in prior period 47 (1,548 ) Increases related to tax positions taken during the current period — — Balance as of the end of the year $ 83 $ 36 These amounts are related to certain deferred tax assets with a corresponding valuation allowance. If recognized, the impact on the Company’s effective tax rate would not not twelve The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes in the accompanying consolidated statements of operations. Accrued interest and penalties, if applicable, are included in accrued expenses and other current liabilities in the consolidated balance sheets. For the years ended December 31, 2022 2021 not The activity related to the tax effected amount of the recognized tax position as follows: Year Ended December 31, 2022 2021 Balance as of the beginning of the year $ (563 ) $ (478 ) Increases related to tax positions in prior period — — Reduction (increase) related to tax position taken during the current period 210 (49 ) Increase related to interest expense (23 ) (36 ) Balance as of the end of the year $ (376 ) $ (563 ) Additional current tax expense has been booked including interest and penalties relating to Venus Concept Australia Pty Ltd. for its historical tax return filing positions, which may not twelve

Note 18 - Segment and Geographi

Note 18 - Segment and Geographic Information	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	18. GEOGRAPHIC INFORMATION Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one not Revenue by geographic location, which is based on the product shipped to location, is summarized as follows: Year Ended December 31, 2022 2021 United States $ 52,101 $ 51,400 International 47,396 54,222 Total revenue $ 99,497 $ 105,622 As of December 31, 2022 December 31, 2021 Revenue by type is a key indicator for providing management with an understanding of the Company’s financial performance, which is organized into four 1. Lease revenue - includes all system sales with typical lease terms of 36 months. 2. System revenue – includes all systems sales with payment terms within 12 months. 3. Product revenue – includes skincare, hair and other consumables payable upon receipt. 4. Service revenue - includes NeoGraft technician services, ad agency services and extended warranty sales. The following table presents revenue by type: Year Ended December 31, 2022 2021 Lease revenue $ 35,267 $ 45,094 System revenue 47,906 43,106 Product revenue 13,316 13,230 Service revenue 3,008 4,192 Total revenue $ 99,497 $ 105,622

Note 19 - Related Party Transac

Note 19 - Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	19. All amounts were at recorded at the exchange amount, which is the amount established and agreed to by the related parties. The following are transactions between the Company and parties related through employment. Sales and Purchases of Securities On November 18, 2022, 2022 1 10:1 2022 2022 Registration Rights Agreements On November 18, 2022, 2022 2022 2021 Distribution Agreements On January 1, 2018, December 31, 2022 2021, In 2020, January 1, 2021, December 31, 2022 2021,

Note 20 - Subsequent Events

Note 20 - Subsequent Events	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	20. Separation of Chief Operation Officer On February 7, 2023, March 6, 2023. March 1, 2023, £315,418.77 March 2022, June 15, 2024 ( ninety 90 £3,400 £2,000 Sale of Stock to LPC Between January 1, 2023, March 22, 2023, 2,865,802 $0.248 16 2022

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and with the instructions to Form 10 X. The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company as of December 31, 2022 not Amounts reported in thousands within this report are computed based on the amounts in dollars. As a result, the sum of the components reported in thousands may not may not In the Form 10 March 31, 2021, May 17, 2021, 10 June 30, 2021, August 17, 2021, 10 September 30, 2021, November 12, 2021 10 December 31, 2021, March 28, 2022, 18 Reclassification Adjustment Three Months Ended Year Ended March 31, 2021 June 30, 2021 September 30, 2021 December 31, 2021 December 31, 2021 United States $ (362 ) $ (615 ) $ (703 ) $ (440 ) $ (2,120 ) International 362 615 703 440 2,120 Total revenue $ — $ — $ — $ — $ — Additionally, the Company performed reclassifications within the Operating Expenses section of the Statements of Operations. The intent was to reclassify clinical affairs costs and clinical training costs previously presented within general and administrative expenses into research and development and selling and marketing expenses, respectively. The following table summarizes the impact of the reclassification adjustment on the Company's Annual Report on Form 10 March 28, 2022, 10 2021 2022: As previously reported Adjustment As reclassified Consolidated statements of operations: For the year ended December 31, 2021 Selling and marketing $ 37,438 $ 4,482 $ 41,920 General and administrative 45,940 (5,870 ) 40,070 Research and development 8,258 1,388 9,646 Condensed consolidated statements of operations for the three months ended: March 31, 2022 Selling and marketing 9,903 1,181 11,084 General and administrative 13,094 (1,622 ) 11,472 Research and development 2,202 441 2,643 March 31, 2021 Selling and marketing 7,854 1,052 8,906 General and administrative 12,165 (1,408 ) 10,757 Research and development 2,051 356 2,407 June 30, 2022 Selling and marketing 9,487 1,036 10,523 General and administrative 14,249 (1,312 ) 12,937 Research and development 2,436 276 2,712 June 30, 2021 Selling and marketing 10,114 1,139 11,253 General and administrative 7,828 (1,468 ) 6,360 Research and development 2,024 329 2,353 September 30, 2022 Selling and marketing 8,094 1,275 9,369 General and administrative 14,128 (1,723 ) 12,405 Research and development 2,576 448 3,024 September 30, 2021 Selling and marketing 8,775 1,035 9,810 General and administrative 11,990 (1,337 ) 10,653 Research and development 1,930 302 2,232
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification of Comparative Amounts The Company previously offset certain Trade Payables with Advances to Suppliers associated with one no not The following table summarizes the impact of the reclassification adjustments on the Company's Form 10 March 28, 2022 2022: As previously reported Adjustment As reclassified Consolidated balance sheets: December 31, 2021 Advances to suppliers $ 2,162 $ 3,505 $ 5,667 Trade payables 4,913 3,505 8,418 March 31, 2022 Advances to suppliers 3,532 2,856 6,388 Trade payables 4,788 2,856 7,644 June 30, 2022 Advances to suppliers 2,869 3,090 5,959 Trade payables 4,184 3,090 7,274 September 30, 2022 Advances to suppliers 3,605 2,186 5,791 Trade payables 6,093 2,186 8,279 The following table summarizes the impact of the reclassification adjustments on the Company's Form 10 March 28, 2022 2022: As previously reported Adjustment As reclassified Consolidated statements of cash flows: For the year ended December 31, 2021 Changes in operating assets and liabilities: Advances to suppliers $ 425 $ (3,505 ) $ (3,080 ) Trade payables (1,409 ) 3,505 2,096 For the three months ended March 31, 2022 Changes in operating assets and liabilities: Advances to suppliers (1,370 ) (2,856 ) (4,226 ) Trade payables (125 ) 2,856 2,731 For the three months ended March 31, 2021 Changes in operating assets and liabilities: Advances to suppliers (1,417 ) (1,680 ) (3,097 ) Trade payables (178 ) 1,680 1,502 For the six months ended June 30, 2022 Changes in operating assets and liabilities: Advances to suppliers (707 ) (3,090 ) (3,797 ) Trade payables (729 ) 3,090 2,361 For the six months ended June 30, 2021 Changes in operating assets and liabilities: Advances to suppliers (772 ) (2,291 ) (3,063 ) Trade payables (640 ) 2,291 1,651 For the nine months ended September 30, 2022 Changes in operating assets and liabilities: Advances to suppliers (1,443 ) (2,186 ) (3,629 ) Trade payables 1,180 2,186 3,366 For the nine months ended September 30, 2021 Changes in operating assets and liabilities: Advances to suppliers (142 ) (2,500 ) (2,642 ) Trade payables (1,573 ) 2,500 927
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Venus Concept Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated on consolidation. Where the Company does not 100%
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The consolidated financial statements are presented in U.S. dollars. Amounts reported in thousands within this report are computed based on the amounts in dollars. As a result, the sum of the components reported in thousands may not may not All exchange gains and losses from remeasurement of monetary balance sheet items resulting from transactions in non-functional currencies are recorded in the consolidated statements of operations as they arise. In respect of transactions denominated in currencies other than the Company and its subsidiaries’ functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are remeasured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these transactions are recognized in the consolidated statements of operations.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, accounts receivable and long-term receivables. The Company’s cash and cash equivalents are invested primarily in deposits with major banks worldwide, as such minimal credit risk exists with respect to such investments. The Company’s trade receivables are derived from global sales to customers. An allowance for doubtful accounts is provided with respect to all balances for which collection is deemed to be doubtful.
Risk and Uncertainties [Policy Text Block]	Risks and Uncertainties While the impact of COVID- 19 19 Besides COVID- 19, not may may The Company has borrowings with interest rates that are subject to fluctuations as charged by the lender. The Company does not December 31, 2022 2021
Concentration of Customers [Policy Text Block]	Concentration of Customers For the years ended December 31, 2022 2021 10% 10%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts Trade accounts receivable do not not may December 31, 2022 2021
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or net realizable value and include raw materials, work in progress and finished goods. Cost is determined as follows: Raw Materials and Work in Progress (“WIP”) – Cost is determined on a standard cost basis utilizing the weighted average cost of historical purchases, which approximates actual cost. The cost of WIP and finished goods includes the cost of raw materials and the applicable share of the cost of labor and fixed and variable production overheads. The Company regularly evaluates the value of inventory based on a combination of factors including the following: historical usage rates, product end of life dates, technological obsolescence and product introductions. The Company includes demonstration units within inventories. Proceeds from the sale of demonstration units are recorded as revenue.
Receivable [Policy Text Block]	Long-term Receivables Long-term receivables relate to the Company’s subscription revenue or contracts which stipulate payment terms which exceed one December 31, 2022 December 31, 2021. Deferred revenues represent payments received prior to the income being earned. Once the equipment has been delivered or the services have been rendered, these amounts are recognized in income.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is between three ten
Lessee, Leases [Policy Text Block]	Leases The Company determines if an agreement is, or contains, a lease at inception. An agreement is, or contains, a lease if the contact conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company leases assets including land and buildings, vehicles, and equipment. For leases with a term of 12 The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. An operating lease is a lease in which a lessor transfers the use of an asset to a lessee for a period of time but does not five i. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. ii. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. iii. The lease term is for a major part (generally 75% iv. The sum of the lease payments and the present value of any residual value guaranteed by the lessee amounts to or exceeds substantially all (generally 90% v. The underlying asset is of such a specialized nature that it is expected to have no For a finance lease, the right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. For an operating lease, amortization of the right-of-use asset is calculated as the difference between the straight-line rent expense and the interest expense on the lease liability for a given period. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability. The lease liability is initially measured at the present value of the lease payments that are not no The lease liabilities are subsequently measured at amortized cost using the effective interest method. They are remeasured when there is a change in future lease payments arising from a change in the lease term, if there is a change in the Company’s estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option. All of our leases for which we are the lessee are operating leases and are included within operating lease right-of-use assets, net, operating lease liabilities, and long-term operating lease liabilities in our Consolidated Balance Sheets.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of customer relationships, brand, technology and supplier agreement. Intangible assets are stated at cost less accumulated amortization. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which range from approximately six fifteen The useful lives of intangible assets are based on the Company’s assessment of various factors impacting estimated cash flows, such as the product’s position in its lifecycle, the existence or absence of like products in the market, various other competitive and regulatory issues, and contractual terms.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company accounts for the impairment of long-lived assets in accordance with FASB, ASC 360 10, may not December 31, 2022 2021
Debt, Policy [Policy Text Block]	Debt Issuance Costs Costs related to the issuance of debt are presented as a direct deduction to the carrying value of the debt and are amortized to accretion expenses using the effective interest rate method over the term of the related debt.
Derivatives, Policy [Policy Text Block]	Derivatives The Company reviews the terms of convertible notes, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Derivative financial instruments are initially measured at their fair value. Derivative financial instruments that are accounted for as liabilities, are initially recorded at fair value and then re-valued at each reporting date, with changes in the fair value recognized in the consolidated statements of operations.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company adopted ASC 606 606” January 1, 2019 not 606 The Company generates revenue from ( 1 2 3 fourth 2021. Many of the Company’s products are sold under subscription contracts with control passing to the customer at the earlier of the end of the term and when the payment is received in full. The subscription contracts include an initial deposit followed by monthly installments typically over a period of 36 months. In accordance with ASC 840 840” The Company recognizes revenues on other products and services in accordance with ASC 606. five 1 2 3 4 5 The Company does not
Cost of Goods and Service [Policy Text Block]	Cost of Goods For subscription sales (qualifying as sales-type lease arrangements) and product sales, the costs are recognized upon shipment to the customer or distributor.
Advertising Cost [Policy Text Block]	Advertising Costs The cost of advertising and media is expensed as incurred. For the years ended December 31, 2022 2021
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Major components of research and development expenses consist of personnel costs, including salaries and benefits, hardware and software research and development costs, and clinical studies.
Standard Product Warranty, Policy [Policy Text Block]	Warranty The Company provides a standard warranty against defects for all of its systems. The warranty period begins upon shipment and is for a period of one three The Company records a liability for accrued warranty costs at the time of sale of a system, which consists of the warranty on products sold based on historical warranty costs and management’s estimates. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts thereof as necessary. The Company also provides an extended warranty service. Extended warranty can be purchased at any time after the purchase of a system and prior to the expiration of the standard warranty provided with the sale of the system. Extended warranty services include standard warranty services. The Company recognizes the revenue from the sale of an extended warranty over the period of the extended warranty and accounts it for separately from the standard warranty.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows the deferred income taxes method of accounting for income taxes. Under this method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying values of accounts and their respective income tax basis. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years during which the temporary differences are expected to be realized or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is included in income in the period that includes the enactment date. The Company establishes valuation allowances when necessary to reduce deferred tax assets to the amounts that are more likely than not not” not not” not
Income Tax Uncertainties, Policy [Policy Text Block]	Uncertain Tax Positions The Company recognizes the effect of income tax positions only if those positions are more likely than not first not second 50% The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, 718” 718 The fair value of stock options (“options”) on the grant date is estimated using the Black-Scholes option-pricing model using the single-option approach. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions, including the option’s expected term and the price volatility of the underlying stock, to determine the fair value of the award. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. The Company has made a policy choice to account for forfeitures when they occur.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share The Company computes net (loss) income per share in accordance with ASC Topic 260, 260” two two not Diluted net (loss) income per share is the same as basic net (loss) income per share for the periods in which the Company had a net loss because the inclusion of outstanding common stock equivalents would be anti-dilutive.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In November 2021, No. 2021 10, 832 December 31, 2021. 14 In February 2016, No. 2016 02 842 2016 02” On January 1, 2022, not The Company elected the optional package of practical expedients to not not As a result of the adoption of ASU 2016 02, no Operating lease ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. Upon adoption of ASU 2016 02, January 1, 2022. 2016 02, January 1, 2022. All real estate leases are recorded on the balance sheet. Equipment and other non-real estate leases with an initial term of twelve not one not may no not The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgment to determine if an asset is specified in the contract and if the Company directs how and for what purpose the asset is used during the term of the contract. In October 2021, No. 2021 08, 805 606, December 15, 2022, not In May 2021, 2021 04, 260 470 50 718 815 40 1 2 December 15, 2021, not In March 2020, 2020 04 848 2021, March 12, 2020 December 31, 2022. may no December 31, 2022. January 2021, may 848. not In December 2019, 2019 12 740 first 2022, not Recently Issued Accounting Standards Not Yet Adopted In August 2020, No. 2020 06 2020 06” 470 20 815 40 2020 06 2020 06 January 1, 2024, No. 2020 06 In February 2020, 2020 02 326 842 326 842. 326, 326 January 1, 2023,

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	Reclassification Adjustment Three Months Ended Year Ended March 31, 2021 June 30, 2021 September 30, 2021 December 31, 2021 December 31, 2021 United States $ (362 ) $ (615 ) $ (703 ) $ (440 ) $ (2,120 ) International 362 615 703 440 2,120 Total revenue $ — $ — $ — $ — $ — As previously reported Adjustment As reclassified Consolidated statements of operations: For the year ended December 31, 2021 Selling and marketing $ 37,438 $ 4,482 $ 41,920 General and administrative 45,940 (5,870 ) 40,070 Research and development 8,258 1,388 9,646 Condensed consolidated statements of operations for the three months ended: March 31, 2022 Selling and marketing 9,903 1,181 11,084 General and administrative 13,094 (1,622 ) 11,472 Research and development 2,202 441 2,643 March 31, 2021 Selling and marketing 7,854 1,052 8,906 General and administrative 12,165 (1,408 ) 10,757 Research and development 2,051 356 2,407 June 30, 2022 Selling and marketing 9,487 1,036 10,523 General and administrative 14,249 (1,312 ) 12,937 Research and development 2,436 276 2,712 June 30, 2021 Selling and marketing 10,114 1,139 11,253 General and administrative 7,828 (1,468 ) 6,360 Research and development 2,024 329 2,353 September 30, 2022 Selling and marketing 8,094 1,275 9,369 General and administrative 14,128 (1,723 ) 12,405 Research and development 2,576 448 3,024 September 30, 2021 Selling and marketing 8,775 1,035 9,810 General and administrative 11,990 (1,337 ) 10,653 Research and development 1,930 302 2,232 As previously reported Adjustment As reclassified Consolidated balance sheets: December 31, 2021 Advances to suppliers $ 2,162 $ 3,505 $ 5,667 Trade payables 4,913 3,505 8,418 March 31, 2022 Advances to suppliers 3,532 2,856 6,388 Trade payables 4,788 2,856 7,644 June 30, 2022 Advances to suppliers 2,869 3,090 5,959 Trade payables 4,184 3,090 7,274 September 30, 2022 Advances to suppliers 3,605 2,186 5,791 Trade payables 6,093 2,186 8,279 As previously reported Adjustment As reclassified Consolidated statements of cash flows: For the year ended December 31, 2021 Changes in operating assets and liabilities: Advances to suppliers $ 425 $ (3,505 ) $ (3,080 ) Trade payables (1,409 ) 3,505 2,096 For the three months ended March 31, 2022 Changes in operating assets and liabilities: Advances to suppliers (1,370 ) (2,856 ) (4,226 ) Trade payables (125 ) 2,856 2,731 For the three months ended March 31, 2021 Changes in operating assets and liabilities: Advances to suppliers (1,417 ) (1,680 ) (3,097 ) Trade payables (178 ) 1,680 1,502 For the six months ended June 30, 2022 Changes in operating assets and liabilities: Advances to suppliers (707 ) (3,090 ) (3,797 ) Trade payables (729 ) 3,090 2,361 For the six months ended June 30, 2021 Changes in operating assets and liabilities: Advances to suppliers (772 ) (2,291 ) (3,063 ) Trade payables (640 ) 2,291 1,651 For the nine months ended September 30, 2022 Changes in operating assets and liabilities: Advances to suppliers (1,443 ) (2,186 ) (3,629 ) Trade payables 1,180 2,186 3,366 For the nine months ended September 30, 2021 Changes in operating assets and liabilities: Advances to suppliers (142 ) (2,500 ) (2,642 ) Trade payables (1,573 ) 2,500 927

Note 3 - Net Loss Per Share (Ta

Note 3 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the year ended December 31, 2022 2021 Numerator: Net loss $ (43,584 ) $ (22,141 ) Net loss allocated to stockholders of the Company $ (43,700 ) $ (23,013 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share, basic and diluted 65,960 54,466 Net loss per share: Basic and diluted $ (0.66 ) $ (0.42 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2022 2021 Options to purchase common stock and restricted stock units ("RSUs") 12,741,394 5,977,179 Preferred stock 31,850,000 3,790,755 Restricted Stock 388,750 - Shares reserved for convertible notes 8,215,706 8,213,880 Warrants for common stock 15,928,867 15,928,867 Total potential dilutive shares 69,124,717 33,910,681

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Fair Value, by Balance Sheet Grouping [Table Text Block]	Fair Value Measurements as of December 31, 2022 Quoted Prices in Active Markets using Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Guaranteed Investment Certificates $ — $ 59 $ — $ 59 Total assets $ — $ 59 $ — $ 59 Fair Value Measurements as of December 31, 2021 Quoted Prices in Active Markets using Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Guaranteed Investment Certificates $ — $ 64 $ — $ 64 Total assets $ — $ 64 $ — $ 64

Note 6 - Accounts Receivable (T

Note 6 - Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	As of December 31, 2022 2021 Gross accounts receivable $ 70,925 $ 86,625 Unearned income (3,354 ) (4,033 ) Allowance for doubtful accounts (13,619 ) (11,997 ) $ 53,952 $ 70,595 Reported as: Current trade receivables $ 37,262 $ 46,918 Current unearned interest income (2,397 ) (2,678 ) Long-term trade receivables 20,044 27,710 Long-term unearned interest income (957 ) (1,355 ) $ 53,952 $ 70,595
Contractual Commitments, Net of Allowance For Doubtful Accounts To Be Received Maturity [Table Text Block]	December 31, Total 2023 2024 2025 2026 2027 Current financing receivables, net of allowance of $ 6,938 $ 20,333 $ 20,333 $ — $ — $ — $ — Long-term financing receivables, net of allowance of $ 906 20,044 — 15,965 4,029 50 — $ 40,377 $ 20,333 $ 15,965 $ 4,029 $ 50 $ —
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	As of December 31, 2022 2021 Balance at beginning of year $ 11,997 $ 18,490 Write-offs (5,715 ) (6,230 ) (Recovery) provision 7,337 (263 ) Balance at end of year $ 13,619 $ 11,997

Note 7 - Select Balance Sheet_2

Note 7 - Select Balance Sheet and Statement of Operations Information (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2022 2021 Raw materials $ 2,478 $ 2,368 Work-in-progress 2,112 1,649 Finished goods 19,316 16,526 Total inventory $ 23,906 $ 20,543
Property, Plant and Equipment [Table Text Block]	December 31, Useful Lives (in years) 2022 2021 Lab equipment tooling and molds 4 – 10 $ 4,356 $ 8,194 Office furniture and equipment 6 – 10 1,240 1,743 Leasehold improvements up to 10 794 1,839 Computers and software 3 906 1,939 Vehicles 5 – 7 37 37 Demo units 5 214 114 Total property and equipment 7,547 13,866 Less: Accumulated depreciation (5,690 ) (11,197 ) Total property and equipment, net $ 1,857 $ 2,669
Schedule of Other Current Assets [Table Text Block]	December 31, 2022 2021 Government remittances (1) $ 1,602 $ 1,322 Consideration receivable from subsidiaries sale 629 1,405 Deferred financing costs 301 223 Sundry assets and miscellaneous 1,170 808 Total other current assets $ 3,702 $ 3,758
Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]	December 31, 2022 2021 Payroll and related expense $ 2,244 $ 1,770 Accrued expenses 5,045 6,584 Commission accrual 3,761 4,529 Sales and consumption taxes 5,617 6,629 Total accrued expenses and other current liabilities $ 16,667 $ 19,512
Schedule of Product Warranty Liability [Table Text Block]	December 31, 2022 2021 Balance as of the beginning of the year $ 1,753 $ 1,639 Warranties issued during the year 993 1,231 Warranty costs incurred during the year (1,264 ) (1,117 ) Balance at the end of the year $ 1,482 $ 1,753 Current 1,074 1,245 Long-term 408 508 Total $ 1,482 $ 1,753
Schedule of Finance Expenses [Table Text Block]	December 31, 2022 2021 Interest expense $ 4,297 $ 3,720 Accretion on long-term debt and amortization of fees 264 1,235 Total finance expenses $ 4,561 $ 4,955

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Lease, Cost [Table Text Block]	Year Ended December 31, 2022 Operating lease cost $ 1,942,765 Short-term lease cost 267,503 Total lease cost $ 2,210,268 Year Ended December 31, 2022 Operating cash outflows from operating leases $ 1,943 Year Ended December 31, 2022 Operating leases Weighted-average remaining lease term 4.2 yrs. Weighted-average discount rate 4.00 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Years ending December 31, Operating leases 2023 $ 1,807 2024 1,409 2025 1,228 2026 1,038 2027 594 Thereafter 544 Imputed Interest (1) (592 ) Total $ 6,028

Note 9 - Intangible Assets an_2

Note 9 - Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	At December 31, 2022 Gross Amount Accumulated Amortization Net Amount Customer relationships $ 1,400 $ (429 ) $ 971 Brand 2,500 (1,066 ) 1,434 Technology 16,900 (8,919 ) 7,981 Supplier agreement 3,000 (1,467 ) 1,533 Total intangible assets $ 23,800 $ (11,881 ) $ 11,919 At December 31, 2021 Gross Amount Accumulated Amortization Net Amount Customer relationships $ 1,400 $ (336 ) $ 1,064 Brand 2,500 (803 ) 1,697 Technology 16,900 (6,103 ) 10,797 Supplier agreement 3,000 (1,165 ) 1,835 Total intangible assets $ 23,800 $ (8,407 ) $ 15,393
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Years ending December 31, 2023 $ 3,473 2024 3,473 2025 3,004 2026 657 2027 657 Thereafter 655 Total $ 11,919

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Contractual Obligation, Fiscal Year Maturity [Table Text Block]	Years ending December 31, Purchase and Service Commitments 2023 $ 21,174,831 2024 — 2025 — 2026 — 2027 — Thereafter — Total $ 21,174,831

Note 11 - Main Street Term Lo_2

Note 11 - Main Street Term Loan (Tables)	12 Months Ended
	Dec. 31, 2022
MSLP Note [Member]
Notes Tables
Schedule of Maturities of Long-Term Debt [Table Text Block]	As of December 31, 2022 2023 $ 11,594 2024 9,870 2025 40,053 Total $ 61,517

Note 12 - Madryn Long-term De_2

Note 12 - Madryn Long-term Debt and Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2022
Secured Subordinated Convertible Notes [Member]
Notes Tables
Schedule of Maturities of Long-Term Debt [Table Text Block]	As of December 31, 2022 2023 $ 2,137 2024 1,628 2025 28,217 Total $ 31,982

Note 15 - Common Stock Reserv_2

Note 15 - Common Stock Reserved for Issuance (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Common Stock Reserved for Issuance [Table Text Block]	December 31, 2022 December 31, 2021 Outstanding common stock warrants 15,928,867 15,928,867 Outstanding stock options and RSUs 13,130,144 5,977,179 Preferred shares 31,850,000 3,790,755 Shares reserved for conversion of future non-voting preferred share issuance 1,209,245 1,209,245 Shares reserved for conversion of future voting preferred share issuance 9,150,000 — Shares reserved for future option grants and RSUs 376,201 589,064 Shares reserved for Lincoln Park 15,814,471 5,222,867 Shares reserved for Madryn Noteholders 8,215,706 8,213,880 Total common stock reserved for issuance 95,674,634 40,931,857

Note 16 - Stockholders Equity (

Note 16 - Stockholders Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2022 2021 Cost of sales $ 73 $ 31 Selling and marketing 576 848 General and administrative 1,195 1,084 Research and development 260 105 Total stock-based compensation $ 2,104 $ 2,068
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2022 2021 Expected term (in years) 6.00 6.00 Risk-free interest rate 2.56-4.20 % 0.98-1.36 % Expected volatility 42.77 % 44.26 % Expected dividend rate 0 % 0 %
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price per Share, $ Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding – January 1, 2022 5,977,179 $ 3.72 7.20 $ 136 Options granted 8,238,250 0.62 209 Options exercised (16,464 ) 1.59 - Options forfeited/cancelled (1,457,571 ) 4.15 — — Outstanding - December 31, 2022 12,741,394 $ 1.67 8.23 $ 209 Exercisable – December 31, 2022 3,376,223 $ 3.78 5.41 $ — Expected to vest – after December 31, 2022 9,365,171 $ 0.91 9.24 $ 209
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Exercise Price Range Number Weighted average remaining contractual term (years) Weighted average Exercise Price Options exercisable Weighted average remaining contractual term (years) Weighted average Exercise Price $0.21 - $3.64 11,915,903 8.47 $ 1.26 2,586,015 5.64 $ 2.58 $4.26 - $7.95 783,523 4.71 6.68 748,243 4.62 6.70 $12.45 - $25.50 24,277 5.75 18.06 24,274 5.75 18.06 $27.00 - $29.25 9,752 2.30 27.01 9,752 2.30 27.01 $36.00 - $63.90 7,939 4.90 45.65 7,939 4.90 45.65 12,741,394 8.23 $ 1.67 3,376,223 5.41 $ 3.78
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Shares Weighted- Average Grant Date Fair Value per Share, $ Outstanding - January 1, 2022 — $ — RSUs granted 396,250 1.30 RSUs forfeited/cancelled (7,500 ) 1.38 Outstanding - December 31, 2022 388,750 $ 1.30

Note 17 - Income Taxes (Tables)

Note 17 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Year Ended December 31, 2022 2021 United States $ (32,045 ) $ (12,260 ) Other jurisdictions (12,261 ) (10,588 ) Loss before income taxes $ (44,306 ) $ (22,848 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2022 2021 Current tax provision (benefit): Federal $ — $ — Foreign (13 ) (542 ) Total current tax provision (benefit) (13 ) (542 ) Deferred tax provision (benefit): Federal — — Foreign (709 ) (165 ) Total deferred tax provision (benefit) $ (709 ) $ (165 ) Total provision (benefit) for income taxes $ (722 ) $ (707 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2022 2021 Loss before income taxes $ (44,306 ) $ (22,848 ) Theoretical tax benefit at the statutory rate ( 21.0 (9,304 ) (4,798 ) Differences in jurisdictional tax rates (1,671 ) (350 ) Valuation allowance 10,015 5,755 Non-deductible expenses 803 (266 ) Other (565 ) (1,048 ) Total income tax (benefit) provision (722 ) (707 ) Net loss $ (43,584 ) $ (22,141 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2022 2021 Deferred tax assets: Property and equipment $ 690 $ 668 Deferred revenue 1,560 647 Allowance for doubtful accounts 3,917 3,133 Intangible assets (785 ) (1,543 ) Non-deductible expenses 10,371 8,694 Warranty and other reserves 1,806 1,159 Other 1,020 610 Loss carryforwards 46,709 38,353 Valuation allowance (64,341 ) (51,437 ) Total deferred tax assets $ 947 $ 284 Deferred tax liabilities: Deferred revenue $ — $ 46 Total deferred tax liabilities $ — $ 46
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2022 2021 Balance as of the beginning of the year $ 36 $ 1,584 Increases (reductions) related to tax positions in prior period 47 (1,548 ) Increases related to tax positions taken during the current period — — Balance as of the end of the year $ 83 $ 36
Schedule of Recognized Tax Benefits [Table Text Block]	Year Ended December 31, 2022 2021 Balance as of the beginning of the year $ (563 ) $ (478 ) Increases related to tax positions in prior period — — Reduction (increase) related to tax position taken during the current period 210 (49 ) Increase related to interest expense (23 ) (36 ) Balance as of the end of the year $ (376 ) $ (563 )

Note 18 - Segment and Geograp_2

Note 18 - Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Year Ended December 31, 2022 2021 United States $ 52,101 $ 51,400 International 47,396 54,222 Total revenue $ 99,497 $ 105,622
Revenue from External Customers by Products and Services [Table Text Block]	Year Ended December 31, 2022 2021 Lease revenue $ 35,267 $ 45,094 System revenue 47,906 43,106 Product revenue 13,316 13,230 Service revenue 3,008 4,192 Total revenue $ 99,497 $ 105,622

Note 1 - Nature of Operations (

Note 1 - Nature of Operations (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		12 Months Ended
	Dec. 15, 2021	Jun. 17, 2020	Nov. 30, 2022	Feb. 28, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 09, 2020	Jun. 16, 2020
Retained Earnings (Accumulated Deficit), Total					$ (224,105)	$ (180,405)
Proceeds from Issuance of Common Stock					$ 2,135	$ 0
Common Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.0001	$ 0.0001	$ 0.0001
Proceeds from Issuance of Private Placement	$ 16,740
Proceeds from Warrant Exercises					$ 0	$ 903
Venus Spain [Member] | Employee Severance and Retention [Member]
Restructuring Charges, Total					$ 102
December 2020 Public Offering Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)				361,200
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)				$ 2.50
Proceeds from Warrant Exercises				$ 903
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Proceeds from Issuance of Private Placement	$ 4,514
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)					7,585,529
Proceeds from Issuance of Private Placement	12,074
Equity Purchase Agreement [Member] | Lincoln Park [Member]
Equity Purchase Agreement, Maximum Offering Amount								$ 31,000
Agreement Term (Year)								2 years
Proceeds from Issuance of Common Stock					$ 272
Stock Issued During Period, Shares, New Issues (in shares)		3,437,087			400,000
Common Stock, Par or Stated Value Per Share (in dollars per share)								$ 0.0001
The 2021 Private Placement [Member]
Proceeds from Issuance of Private Placement	$ 16,999				$ 0	$ 16,740
The 2021 Private Placement [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,790,755
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
The 2021 Private Placement [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)	9,808,418
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001					$ 0.0001
The 2022 Private Placement [Member]
Proceeds from Issuance of Private Placement			$ 6,720		$ 6,518	$ 0
The 2022 Private Placement [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			3,185,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001
The 2022 Private Placement [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,750,000
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Accounts Receivable, Allowance for Credit Loss, Current	$ 13,619	$ 11,997
Impairment, Long-Lived Asset, Held-for-Use, Total	$ 0	0
Lessor, Sales-type Lease, Term of Contract (Month)	36 months
Advertising Expense	$ 1,776	1,821
Operating Lease, Right-of-Use Asset	5,862	$ 0
Operating Lease, Liability, Total	6,028
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset	5,862
Operating Lease, Liability, Total	$ 6,028
Minimum [Member]
Discount Based Implicit Interest Rate in Subscription Lease	8%	8%
Property, Plant and Equipment, Useful Life (Year)	3 years
Finite-Lived Intangible Asset, Useful Life (Year)	6 years
Standard Product Warranty, Term (Year)	1 year
Maximum [Member]
Discount Based Implicit Interest Rate in Subscription Lease	10%	9%
Property, Plant and Equipment, Useful Life (Year)	10 years
Finite-Lived Intangible Asset, Useful Life (Year)	15 years
Standard Product Warranty, Term (Year)	3 years
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member]
Number of Major Customers	0	0
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers	0	0

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Reclassification Adjustment (Details) - USD ($) $ in Thousands	3 Months Ended							12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Revenue, reclassification adjustment								$ 99,497	$ 105,622
Revenues								99,497	105,622
Selling and marketing	$ 9,369	$ 10,523	$ 11,084		$ 9,810	$ 11,253	$ 8,906	40,276	41,920
General and administrative	12,405	12,937	11,472		10,653	6,360	10,757	49,618	40,070
Research and development	3,024	2,712	2,643		2,232	2,353	2,407	10,953	9,646
Advances to suppliers	5,791	5,959	6,388	$ 5,667				5,881	5,667
Trade payables	8,279	7,274	7,644	8,418				8,033	8,418
Advances to suppliers	(3,629)	(3,797)	(4,226)		(2,642)	(3,063)	(3,097)	(214)	(3,080)
Trade payables	3,366	2,361	2,731		927	1,651	1,502	(385)	2,096
UNITED STATES
Revenue, reclassification adjustment								52,101	51,400
Non-US [Member]
Revenue, reclassification adjustment								$ 47,396	54,222
Revision of Prior Period, Error Correction, Adjustment [Member]
Revenues				0	0	0	0		0
Advances to suppliers	2,186	3,090	2,856	3,505					3,505
Trade payables	2,186	3,090	2,856	3,505					3,505
Advances to suppliers	(2,186)	(3,090)	(2,856)		(2,500)	(2,291)	(1,680)		(3,505)
Trade payables	2,186	3,090	2,856		2,500	2,291	1,680		3,505
Revision of Prior Period, Error Correction, Adjustment [Member] | UNITED STATES
Revenue, reclassification adjustment				(440)	(703)	(615)	(362)		(2,120)
Revision of Prior Period, Error Correction, Adjustment [Member] | Non-US [Member]
Revenue, reclassification adjustment				440	703	615	362		2,120
Previously Reported [Member]
Selling and marketing	8,094	9,487	9,903		8,775	10,114	7,854		37,438
General and administrative	14,128	14,249	13,094		11,990	7,828	12,165		45,940
Research and development	2,576	2,436	2,202		1,930	2,024	2,051		8,258
Advances to suppliers	3,605	2,869	3,532	2,162					2,162
Trade payables	6,093	4,184	4,788	$ 4,913					4,913
Advances to suppliers	(1,443)	(707)	(1,370)		(142)	(772)	(1,417)		425
Trade payables	1,180	(729)	(125)		(1,573)	(640)	(178)		(1,409)
Revision of Prior Period, Reclassification, Adjustment [Member]
Selling and marketing	1,275	1,036	1,181		1,035	1,139	1,052		4,482
General and administrative	(1,723)	(1,312)	(1,622)		(1,337)	(1,468)	(1,408)		(5,870)
Research and development	$ 448	$ 276	$ 441		$ 302	$ 329	$ 356		$ 1,388

Note 3 - Net Loss Per Share - C

Note 3 - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Net loss	$ (43,584)	$ (22,141)
Net loss allocated to stockholders of the Company	$ (43,700)	$ (23,013)
Weighted-average shares of common stock outstanding used in computing net loss per share, basic and diluted (in shares)	65,960	54,466
Basic (in dollars per share)	$ (0.66)	$ (0.42)

Note 3 - Net Loss Per Share - A

Note 3 - Net Loss Per Share - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total potential dilutive shares (in shares)	69,124,717	33,910,681
Share-Based Payment Arrangement, Option [Member]
Total potential dilutive shares (in shares)	12,741,394	5,977,179
Performance Shares [Member]
Total potential dilutive shares (in shares)	31,850,000	3,790,755
Restricted Stock [Member]
Total potential dilutive shares (in shares)	388,750	0
Shares Reserved for Convertible Notes [Member]
Total potential dilutive shares (in shares)	8,215,706	8,213,880
Warrant [Member]
Total potential dilutive shares (in shares)	15,928,867	15,928,867

Note 4 - Sale of Subsidiaries (

Note 4 - Sale of Subsidiaries (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 07, 2021
Gain (Loss) on Disposition of Stock in Subsidiary	$ (1,482)	$ (567)
Proceeds from Divestiture of Businesses, Net of Cash Divested, Total	0	$ (40)
Venus Concept Shanghai Co.Ltd [Member]
Business Acquisition, Percentage of Voting Interests Acquired				45%
Maximum [Member]
Percentage of Operating Revenue of Disposed Subsidiaries of Total Revenue		15%
Venus Concept Africa (Pty) Ltd. [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Disposal Group, Including Discontinued Operation, Percentage of Ownership		80%
Gain (Loss) on Disposition of Stock in Subsidiary	0	$ (188)
Venus Aesthetic LLP [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Disposal Group, Including Discontinued Operation, Percentage of Ownership			51%
Gain (Loss) on Disposition of Stock in Subsidiary			$ (579)
Proceeds from Divestiture of Businesses, Net of Cash Divested, Total			$ 400
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down		$ 379
Venus Concept France SAS [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Gain (Loss) on Disposition of Stock in Subsidiary	$ (60)

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurements - Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets, fair value	$ 59	$ 64
Guaranteed Investment Certificates [Member]
Assets, fair value	59	64
Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Guaranteed Investment Certificates [Member]
Assets, fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	59	64
Fair Value, Inputs, Level 2 [Member] | Guaranteed Investment Certificates [Member]
Assets, fair value	59	64
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Fair Value, Inputs, Level 3 [Member] | Guaranteed Investment Certificates [Member]
Assets, fair value	$ 0	$ 0

Note 6 - Accounts Receivable (D

Note 6 - Accounts Receivable (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lessor, Sales-type Lease, Term of Contract (Month)	36 months
Sales-type and Direct Financing Leases, Lease Receivable	$ 40,377	$ 53,887
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 13,619	$ 11,997	$ 18,490

Note 6 - Accounts Receivable -

Note 6 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Gross accounts receivable	$ 70,925	$ 86,625
Unearned income	(3,354)	(4,033)
Allowance for doubtful accounts	(13,619)	(11,997)	$ (18,490)
Accounts Receivable, after Allowance for Credit Loss, Total	53,952	70,595
Current trade receivables	37,262	46,918
Current unearned interest income	(2,397)	(2,678)
Long-term trade receivables	20,044	27,710
Long-term unearned interest income	$ (957)	$ (1,355)

Note 6 - Accounts Receivable _2

Note 6 - Accounts Receivable - Schedule of Contractual Commitments, Net of Allowance for Doubtful Accounts (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Total, current financing receivables, net	$ 40,377
2023, current financing receivables, net	20,333
2024, current financing receivables, net	15,965
2025, current financing receivables, net	4,029
2026, current financing receivables, net	50
2027, current financing receivables, net	0
Current Financing Receivables, Net Of Allowance [Member]
Total, current financing receivables, net	20,333
2023, current financing receivables, net	20,333
2024, current financing receivables, net	0
2025, current financing receivables, net	0
2026, current financing receivables, net	0
2027, current financing receivables, net	0
Noncurrent Financing Receivables, Net Of Allowance [Member]
Total, current financing receivables, net	20,044
2023, current financing receivables, net	0
2024, current financing receivables, net	15,965
2025, current financing receivables, net	4,029
2026, current financing receivables, net	50
2027, current financing receivables, net	$ 0

Note 6 - Accounts Receivable _3

Note 6 - Accounts Receivable - Schedule of Contractual Commitments, Net of Allowance for Doubtful Accounts (Details) (Parentheticals) $ in Thousands	Dec. 31, 2022 USD ($)
Current Financing Receivables, Net Of Allowance [Member]
Allowance, current financing receivables, net	$ 6,938
Noncurrent Financing Receivables, Net Of Allowance [Member]
Allowance, long-term financing receivables, net	$ 906

Note 6 - Accounts Receivable _4

Note 6 - Accounts Receivable - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 11,997	$ 18,490
Write-offs	(5,715)	(6,230)
(Recovery) provision	7,337	(263)
Balance	$ 13,619	$ 11,997

Note 7 - Select Balance Sheet_3

Note 7 - Select Balance Sheet and Statement of Operations Information (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cost, Direct Material	$ 31,555	$ 28,089
Inventory Valuation Reserves	3,258	2,213
Depreciation, Total	$ 990	$ 1,381

Note 7 - Select Balance Sheet_4

Note 7 - Select Balance Sheet and Statement of Operations Information - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Raw materials	$ 2,478	$ 2,368
Work-in-progress	2,112	1,649
Finished goods	19,316	16,526
Total inventory	$ 23,906	$ 20,543

Note 7 - Select Balance Sheet_5

Note 7 - Select Balance Sheet and Statement of Operations Information - Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lab equipment tooling and molds	$ 4,356	$ 8,194
Office furniture and equipment	1,240	1,743
Leasehold improvements	794	1,839
Computers and software	906	1,939
Demo units	214	114
Total property and equipment	7,547	13,866
Less: Accumulated depreciation	(5,690)	(11,197)
Total property and equipment, net	$ 1,857	2,669
Tools, Dies and Molds [Member] | Minimum [Member]
Property and equipment, Useful lives	4
Tools, Dies and Molds [Member] | Maximum [Member]
Property and equipment, Useful lives	10
Office Equipment [Member] | Minimum [Member]
Property and equipment, Useful lives	6
Office Equipment [Member] | Maximum [Member]
Property and equipment, Useful lives	10
Leasehold Improvements [Member] | Maximum [Member]
Property and equipment, Useful lives	up to 10
Computer Equipment [Member]
Property and equipment, Useful lives	3
Vehicles [Member]
Vehicles	$ 37	$ 37
Vehicles [Member] | Minimum [Member]
Property and equipment, Useful lives	5
Vehicles [Member] | Maximum [Member]
Property and equipment, Useful lives	7
Demo Units [Member]
Property and equipment, Useful lives	5

Note 7 - Select Balance Sheet_6

Note 7 - Select Balance Sheet and Statement of Operations Information - Other Current Assets (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Government remittances (1)	[1]	$ 1,602	$ 1,322
Consideration receivable from subsidiaries sale		629	1,405
Deferred financing costs		301	223
Sundry assets and miscellaneous		1,170	808
Total other current assets		$ 3,702	$ 3,758
[1]Government remittances are receivables from the local tax authorities for refund of sales taxes and income taxes.

Note 7 - Select Balance Sheet_7

Note 7 - Select Balance Sheet and Statement of Operations Information - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payroll and related expense	$ 2,244	$ 1,770
Accrued expenses	5,045	6,584
Commission accrual	3,761	4,529
Sales and consumption taxes	5,617	6,629
Total accrued expenses and other current liabilities	$ 16,667	$ 19,512

Note 7 - Select Balance Sheet_8

Note 7 - Select Balance Sheet and Statement of Operations Information - Warranty Accrual (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance as of the beginning of the year	$ 1,753	$ 1,639
Warranties issued during the year	993	1,231
Warranty costs incurred during the year	(1,264)	(1,117)
Balance at the end of the year	1,482	1,753
Current	1,074	1,245
Long-term	408	508
Total	$ 1,482	$ 1,753

Note 7 - Select Balance Sheet_9

Note 7 - Select Balance Sheet and Statement of Operations Information - Finance Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Interest expense	$ 4,297	$ 3,720
Accretion on long-term debt and amortization of fees	264	1,235
Total finance expenses	$ 4,561	$ 4,955

Note 8 - Leases - Lease Cost (D

Note 8 - Leases - Lease Cost (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Operating lease cost	$ 1,942,765
Short-term lease cost	267,503
Total lease cost	2,210,268
Operating cash outflows from operating leases	$ 1,943,000
Weighted-average remaining lease term (Year)	4 years 2 months 12 days
Weighted-average discount rate	4%

Note 8 - Leases - Operating Lea

Note 8 - Leases - Operating Lease Maturity (Details) $ in Thousands	Dec. 31, 2022 USD ($)
2023, operating lease	$ 1,807
2024, operating lease	1,409
2025, operating lease	1,228
2026, operating lease	1,038
2027, operating lease	594
Thereafter, operating lease	544
Imputed Interest (1)	(592)
Total	$ 6,028

Note 9 - Intangible Assets an_3

Note 9 - Intangible Assets and Goodwill (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Nov. 07, 2019
Goodwill, Impairment Loss	$ 0	$ 0
Amortization of Intangible Assets, Total	$ 3,473	$ 3,473
Venus Concept Ltd. [Member] | Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total			$ 16,900
Venus Concept Ltd. [Member] | Brand Name [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total			$ 1,200

Note 9 - Intangible Assets an_4

Note 9 - Intangible Assets and Goodwill - Schedule of Intangible Assets Net of Accumulated Amortization and Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Gross Amount	$ 23,800	$ 23,800
Accumulated amortization	(11,881)	(8,407)
Net Amount	11,919	15,393
Customer Relationships [Member]
Gross Amount	1,400	1,400
Accumulated amortization	(429)	(336)
Net Amount	971	1,064
Brand [Member]
Gross Amount	2,500	2,500
Accumulated amortization	(1,066)	(803)
Net Amount	1,434	1,697
Technology [Member]
Gross Amount	16,900	16,900
Accumulated amortization	(8,919)	(6,103)
Net Amount	7,981	10,797
Supplier Agreement [Member]
Gross Amount	3,000	3,000
Accumulated amortization	(1,467)	(1,165)
Net Amount	$ 1,533	$ 1,835

Note 9 - Intangible Assets an_5

Note 9 - Intangible Assets and Goodwill - Estimated Amortization (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023	$ 3,473
2024	3,473
2025	3,004
2026	657
2027	657
Thereafter	655
Total	$ 11,919	$ 15,393

Note 10 - Commitments and Con_3

Note 10 - Commitments and Contingencies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Purchase Obligation, Total	$ 21,174,831
Contract Manufacturers [Member]
Purchase Obligation, Total	20,775
Open Purchase Order [Member]
Purchase Obligation, Total	$ 1,599
Percentage Of Open Purchase Order	25%

Note 10 - Commitments and Con_4

Note 10 - Commitments and Contingencies - Contractual Obligation Maturity (Details) $ in Thousands	Dec. 31, 2022 USD ($)
2023	$ 21,174,831
2024	0
2025	0
2026	0
2027	0
Thereafter	0
Total	$ 21,174,831

Note 11 - Main Street Term Lo_3

Note 11 - Main Street Term Loan (Details Textual) - MSLP Note [Member]		12 Months Ended
	Dec. 08, 2020	Dec. 08, 2024
Debt Instrument, Term (Year)	5 years
Forecast [Member]
Debt Instrument, Percentage of Outstanding Principal to be Paid with Accrued Unpaid Interest		15%
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	3%

Note 11 - Main Street Term Lo_4

Note 11 - Main Street Term Loan - Schedule Payments on Outstanding Borrowings (Details) - MSLP Note [Member] $ in Thousands	Dec. 31, 2022 USD ($)
2023	$ 11,594
2024	9,870
2025	40,053
Total	$ 61,517

Note 12 - Madryn Long-term De_3

Note 12 - Madryn Long-term Debt and Convertible Notes (Details Textual) - USD ($)		12 Months Ended
	Dec. 09, 2020	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2020	Oct. 11, 2016
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Madryn Credit Agreement [Member]
Repayments of Debt	$ 42,500,000
Madryn Credit Agreement [Member] | Madryn Noteholders [Member]
Debt Instrument, Face Amount					$ 70,000,000
Madryn Credit Agreement [Member] | Madryn Noteholders [Member] | Term A-1, A-2 and B Tranches of Debt [Member]
Long-term Debt, Gross				$ 60,000,000
Secured Subordinated Convertible Notes [Member] | Madryn Noteholders [Member]
Debt Instrument, Default, Increase in Interest Rate	4%
Debt Instrument, Termination, Minimum Principal Outstanding	$ 10,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 3.25
Interest Expense, Total		$ 2,165,000	$ 2,158,000
Repayments of Long-term Debt, Total		$ 0	$ 0
Debt Instrument, Maturity Date	Dec. 09, 2025
Secured Subordinated Convertible Notes [Member] | Madryn Noteholders [Member] | Original Issuance Of Notes To Third Anniversary Date [Member]
Debt Instrument, Interest Rate, Stated Percentage	8%
Secured Subordinated Convertible Notes [Member] | Madryn Noteholders [Member] | After the Third Anniversary [Member]
Debt Instrument, Interest Rate, Stated Percentage	6%

Note 12 - Madryn Long-term De_4

Note 12 - Madryn Long-term Debt and Convertible Notes - Scheduled Payments (Details) - Secured Subordinated Convertible Notes [Member] $ in Thousands	Dec. 31, 2022 USD ($)
2023	$ 2,137
2024	1,628
2025	28,217
Total	$ 31,982

Note 13 - Credit Facility (Deta

Note 13 - Credit Facility (Details Textual) - City National Bank of Florida [Member] - USD ($) $ in Millions	Aug. 26, 2021	Dec. 09, 2020
CNB Note [Member]
Debt Instrument, Face Amount	$ 5
Debt Instrument, Maturity Date	Jul. 24, 2023
Revolving Credit Facility [Member]
Line of Credit Facility, Minimum Deposit Required	$ 1.5	$ 3
Loan Processing Fee		1
Line of Credit Facility, Maximum Borrowing Capacity	$ 5	$ 10
Debt Instrument, LIBOR Floor	0.50%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	3.25%

Note 14 - Government Assistan_2

Note 14 - Government Assistance Programs (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 29, 2020	Apr. 30, 2022	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Aug. 29, 2020	Apr. 20, 2020
Repayments of Secured Debt				$ 543	$ 738
SBA CARES Act Paycheck Protection Program [Member]
Proceeds from Loans	$ 4,048
Repayments of Secured Debt		$ 136	$ 407
Long-Term Debt, Total				$ 0	543
SBA CARES Act Paycheck Protection Program [Member] | Venus Concept Inc [Member]
Debt Instrument, Face Amount						$ 1,665
Debt Instrument, Decrease, Forgiveness					1,086
SBA CARES Act Paycheck Protection Program [Member] | Venus USA [Member]
Debt Instrument, Face Amount							$ 2,383
Debt Instrument, Decrease, Forgiveness					$ 1,689

Note 15 - Common Stock Reserv_3

Note 15 - Common Stock Reserved for Issuance - Common Stock Reserved for Issuance (Details) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Outstanding stock options and RSUs (in dollars per share)	$ 13,130,144	$ 5,977,179
Shares reserved for future option grants and RSUs (in shares)	376,201	589,064
Total common stock reserved for issuance (in shares)	95,674,634	40,931,857
Lincoln Park [Member]
Total common stock reserved for issuance (in shares)	15,814,471	5,222,867
Madryn Noteholders [Member]
Total common stock reserved for issuance (in shares)	8,215,706	8,213,880
Non-Voting Preferred Stock [Member]
Shares reserved for conversion of future preferred share issuance (in shares)	1,209,245	1,209,245
Voting Preferred Stock [Member]
Shares reserved for conversion of future preferred share issuance (in shares)	9,150,000	0
Common Stock [Member]
Outstanding common stock warrants (in shares)	15,928,867	15,928,867
Preferred Stock [Member]
Preferred shares (in shares)	31,850,000	3,790,755

Note 16 - Stockholders Equity_2

Note 16 - Stockholders Equity (Details Textual) $ / shares in Units, $ in Thousands					1 Months Ended			12 Months Ended		24 Months Ended
	Nov. 18, 2022 USD ($) shares	Jul. 12, 2022 USD ($) $ / shares shares	Dec. 15, 2021 USD ($) $ / shares shares	Jun. 17, 2020 shares	Nov. 30, 2022 USD ($) $ / shares shares	Nov. 30, 2017	Nov. 30, 2010	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 09, 2020 $ / shares	Jun. 16, 2020 USD ($) $ / shares shares	Oct. 04, 2019 shares
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares								$ 0.0001	$ 0.0001		$ 0.0001
Proceeds from Issuance of Common Stock								$ 2,135	$ 0
Stock Issued During Period, Value, New Issues								2,204
Proceeds from Issuance of Private Placement			$ 16,740
Payments of Stock Issuance Costs								$ 202
Adjustments to Additional Paid in Capital, Convertible Preferred Stock with Beneficial Conversion Feature			152						$ 152
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | shares								95,674,634	40,931,857
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments								$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value								$ 0	$ 92
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares								$ 0.62	$ 2.20
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value								$ 1,645	$ 1,545
The 2010 Share Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						10 years	7 years
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | shares								94,254	212,650
The 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | shares													450,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | shares								281,947	376,414
Share-based Compensation Arrangement by Share-based Payment Award, Increase in Authorized Shares, Percentage of Outstanding Stock Maximum								4%
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares								7,585,529
Stock Issued During Period, Value, New Issues								$ 1
Proceeds from Issuance of Private Placement			$ 12,074
Adjustments to Additional Paid in Capital, Convertible Preferred Stock with Beneficial Conversion Feature									$ 0
Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares								31,850,000	3,790,755
Series A Preferred Stock [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares									$ 1.29
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.0001
Proceeds from Issuance of Private Placement			$ 4,514
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares									3,790,755
Preferred Stock, Convertible, Conversion Ratio									1
Preferred Stock, Maximum Conversion Cap Percentage									9.99%
Dividends Payable									$ 0
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares									$ 1.25
Adjustments to Additional Paid in Capital, Convertible Preferred Stock with Beneficial Conversion Feature									$ 152
Series A Preferred Stock [Member] | Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares								0
Stock Issued During Period, Value, New Issues								$ 0
Adjustments to Additional Paid in Capital, Convertible Preferred Stock with Beneficial Conversion Feature									0
Voting Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Ratio					10
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares					$ 2
Preferred Stock, Convertible, Volume Weighted Average Price Per Common Share (in dollars per share) | $ / shares					$ 1.25
Voting Preferred Stock [Member] | Preferred Stock [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	3,185,000
Equity Purchase Agreement [Member] | Lincoln Park [Member]
Equity Purchase Agreement, Maximum Offering Amount												$ 31,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares												$ 0.0001
Equity Purchase Agreement, Maximum Shares Issuable (in shares) | shares												7,763,411
Equity Agreement, Maximum Percentage of Stock Outstanding												19.99%
Equity Agreement, Minimum Average Purchase Price (in dollars per share) | $ / shares												$ 3.9755
Maximum Percentage of Outstanding Stock, Beneficial Ownership												9.99%
Stock Issued During Period, Shares, New Issues (in shares) | shares				3,437,087				400,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares										$ 2.70
Stock Issued During Period, Shares, Commitment Fee (in shares) | shares										209,566,000
Stock Issued During Period, Value, Commitment Fee										$ 620
Deferred Offering Costs								$ 0		$ 123
Proceeds from Issuance of Common Stock								$ 272
LPC Purchase Agreement 2022 [Member] | Lincoln Park [Member]
Equity Purchase Agreement, Maximum Offering Amount		$ 11,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares		$ 0.0001
Equity Purchase Agreement, Maximum Shares Issuable (in shares) | shares		12,873,368
Equity Agreement, Maximum Percentage of Stock Outstanding		19.99%
Maximum Percentage of Outstanding Stock, Beneficial Ownership		9.99%
Stock Issued During Period, Shares, New Issues (in shares) | shares								6,500,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares								$ 0.30
Stock Issued During Period, Shares, Commitment Fee (in shares) | shares		685,529
Stock Issued During Period, Value, Commitment Fee		$ 330
Stock Issued During Period, Value, New Issues								$ 1,970
The 2021 Private Placement [Member]
Proceeds from Issuance of Private Placement			16,999					0	$ 16,740
Payments of Stock Issuance Costs			$ 259
The 2021 Private Placement [Member] | Common Stock [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.0001						$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares) | shares			9,808,418
The 2021 Private Placement [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares									9,808,418
The 2021 Private Placement [Member] | Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares									3,790,755
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares									$ 0.0001
Preferred Stock, Convertible, Shares Issuable (in shares) | shares									3,790,755
The 2021 Private Placement [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares			3,790,755
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.0001
The 2022 Private Placement [Member]
Proceeds from Issuance of Private Placement					$ 6,720			$ 6,518	$ 0
Payments of Stock Issuance Costs					$ 202				$ 259
The 2022 Private Placement [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member]
Proceeds from Issuance of Private Placement	$ 6,720
The 2022 Private Placement [Member] | Common Stock [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares					$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares) | shares					1,750,000
The 2022 Private Placement [Member] | Common Stock [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	1,750,000
The 2022 Private Placement [Member] | Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares					3,185,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares					$ 0.0001
Preferred Stock, Convertible, Shares Issuable (in shares) | shares					31,850,000
The 2022 Private Placement [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares					3,185,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares					$ 0.0001
The 2022 Private Placement [Member] | Voting Preferred Stock [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member]
Preferred Stock, Convertible, Conversion Ratio	10
The 2022 Private Placement [Member] | Voting Preferred Stock [Member] | Preferred Stock [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	3,185,000

Note 16 - Stockholders Equity -

Note 16 - Stockholders Equity - Stock-based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total stock-based compensation	$ 2,104	$ 2,068
Cost of Sales [Member]
Total stock-based compensation	73	31
Selling and Marketing Expense [Member]
Total stock-based compensation	576	848
General and Administrative Expense [Member]
Total stock-based compensation	1,195	1,084
Research and Development Expense [Member]
Total stock-based compensation	$ 260	$ 105

Note 16 - Stockholders Equity_3

Note 16 - Stockholders Equity - Stock Options Assumptions (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Expected term (in years) (Year)	6 years
Expected volatility	42.77%	44.26%
Expected dividend rate	0%	0%
Minimum [Member]
Risk-free interest rate	2.56%	0.98%
Maximum [Member]
Risk-free interest rate	4.20%	1.36%

Note 16 - Stockholders Equity_4

Note 16 - Stockholders Equity - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Outstanding, number of shares (in shares)	5,977,179
Outstanding, weighted average exercise price (in dollars per share)	$ 3.72
Outstanding, weighted average remaining contractual term (Year)	8 years 2 months 23 days	7 years 2 months 12 days
Outstanding, aggregate intrinsic value	$ 209	$ 136
Options granted, number of shares (in shares)	8,238,250
Options granted, weighted average exercise price (in dollars per share)	$ 0.62
Options granted, aggregate intrinsic value	$ 209
Options exercised, number of shares (in shares)	(16,464)
Options exercised, weighted average exercise price (in dollars per share)	$ 1.59
Options exercised, aggregate intrinsic value	$ 0	$ 92
Options forfeited/cancelled, number of shares (in shares)	(1,457,571)
Options forfeited/cancelled, weighted average exercise price (in dollars per share)	$ 4.15
Options forfeited/cancelled, aggregate intrinsic value (in dollars per share)	$ 0
Outstanding, number of shares (in shares)	12,741,394	5,977,179
Outstanding, weighted average exercise price (in dollars per share)	$ 1.67	$ 3.72
Exercisable, number of shares (in shares)	3,376,223
Exercisable, weighted average exercise price (in dollars per share)	$ 3.78
Exercisable, weighted average remaining contractual term (Year)	5 years 4 months 28 days
Exercisable, aggregate intrinsic value	$ 0
Expected to vest, number of shares (in shares)	9,365,171
Expected to vest, weighted average exercise price (in dollars per share)	$ 0.91
Expected to vest, weighted average remaining contractual term (Year)	9 years 2 months 26 days
Expected to vest, aggregate intrinsic value	$ 209

Note 16 - Stockholders Equity_5

Note 16 - Stockholders Equity - Stock Options Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Options outstanding, number (in shares)	12,741,394
Options outstanding, weighted average remaining contractual term (Year)	8 years 2 months 23 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.67
Options exercisable (in shares)		3,376,223
Options exercisable, weighted average remaining contractual term (Year)		5 years 4 months 28 days
Options exercisable, weighted average exercise price (in dollars per share)		$ 3.78
Range One [Member]
Exercise price range, lower limit (in dollars per share)	0.21
Exercise price range, upper limit (in dollars per share)	$ 3.64
Options outstanding, number (in shares)	11,915,903
Options outstanding, weighted average remaining contractual term (Year)	8 years 5 months 19 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.26
Options exercisable (in shares)		2,586,015
Options exercisable, weighted average remaining contractual term (Year)		5 years 7 months 20 days
Options exercisable, weighted average exercise price (in dollars per share)		$ 2.58
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	4.26
Exercise price range, upper limit (in dollars per share)	$ 7.95
Options outstanding, number (in shares)	783,523
Options outstanding, weighted average remaining contractual term (Year)	4 years 8 months 15 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.68
Options exercisable (in shares)		748,243
Options exercisable, weighted average remaining contractual term (Year)		4 years 7 months 13 days
Options exercisable, weighted average exercise price (in dollars per share)		$ 6.70
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	12.45
Exercise price range, upper limit (in dollars per share)	$ 25.50
Options outstanding, number (in shares)	24,277
Options outstanding, weighted average remaining contractual term (Year)	5 years 9 months
Options outstanding, weighted average exercise price (in dollars per share)	$ 18.06
Options exercisable (in shares)		24,274
Options exercisable, weighted average remaining contractual term (Year)		5 years 9 months
Options exercisable, weighted average exercise price (in dollars per share)		$ 18.06
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	27
Exercise price range, upper limit (in dollars per share)	$ 29.25
Options outstanding, number (in shares)	9,752
Options outstanding, weighted average remaining contractual term (Year)	2 years 3 months 18 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 27.01
Options exercisable (in shares)		9,752
Options exercisable, weighted average remaining contractual term (Year)		2 years 3 months 18 days
Options exercisable, weighted average exercise price (in dollars per share)		$ 27.01
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	36
Exercise price range, upper limit (in dollars per share)	$ 63.90
Options outstanding, number (in shares)	7,939
Options outstanding, weighted average remaining contractual term (Year)	4 years 10 months 24 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 45.65
Options exercisable (in shares)		7,939
Options exercisable, weighted average remaining contractual term (Year)		4 years 10 months 24 days
Options exercisable, weighted average exercise price (in dollars per share)		$ 45.65

Note 16 - Stockholders Equity_6

Note 16 - Stockholders Equity - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Outstanding (in shares) | shares	0
Outstanding (in dollars per share) | $ / shares	$ 0
RSUs granted (in shares) | shares	396,250
RSUs granted (in dollars per share) | $ / shares	$ 1.30
RSUs forfeited/cancelled (in shares) | shares	(7,500)
RSUs forfeited/cancelled (in dollars per share) | $ / shares	$ 1.38
Outstanding (in shares) | shares	388,750
Outstanding (in dollars per share) | $ / shares	$ 1.30

Note 17 - Income Taxes (Details

Note 17 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets, Valuation Allowance	$ 64,341	$ 51,437
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	12,904	31,150
Deferred Tax Assets, Net of Valuation Allowance, Total	947	284
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	276		$ 0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	$ 191,313	$ 163,395

Note 17 - Income Taxes - Schedu

Note 17 - Income Taxes - Schedule of Geographical Breakdown of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
United States	$ (32,045)	$ (12,260)
Other jurisdictions	(12,261)	(10,588)
Loss before income taxes	$ (44,306)	$ (22,848)

Note 17 - Income Taxes - Sche_2

Note 17 - Income Taxes - Schedule of Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current tax provision (benefit):
Federal	$ 0	$ 0
Foreign	(13)	(542)
Total current tax provision (benefit)	(13)	(542)
Deferred tax provision (benefit):
Federal	0	0
Foreign	(709)	(165)
Total deferred tax provision (benefit)	(709)	(165)
Total provision (benefit) for income taxes	$ (722)	$ (707)

Note 17 - Income Taxes - Reconc

Note 17 - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Loss before income taxes	$ (44,306)	$ (22,848)
Theoretical tax benefit at the statutory rate (21.0% in 2022 and 2021)	(9,304)	(4,798)
Differences in jurisdictional tax rates	(1,671)	(350)
Valuation allowance	10,015	5,755
Non-deductible expenses	803	(266)
Other	(565)	(1,048)
Total provision (benefit) for income taxes	(722)	(707)
Net loss	$ (43,584)	$ (22,141)

Note 17 - Income Taxes - Reco_2

Note 17 - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statutory Rate	21%	21%

Note 17 - Income Taxes - Sche_3

Note 17 - Income Taxes - Schedule of Components of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Property and equipment	$ 690	$ 668
Deferred revenue	1,560	647
Allowance for doubtful accounts	3,917	3,133
Intangible assets	(785)	(1,543)
Non-deductible expenses	10,371	8,694
Warranty and other reserves	1,806	1,159
Other	1,020	610
Loss carryforwards	46,709	38,353
Valuation allowance	(64,341)	(51,437)
Total deferred tax assets	947	284
Deferred tax liabilities:
Deferred revenue	0	46
Total deferred tax liabilities	$ 0	$ 46

Note 17 - Income Taxes - Sche_4

Note 17 - Income Taxes - Schedule of Reconciliation of Uncertain Tax Position (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance as of the beginning of the year	$ 36	$ 1,584
Increases related to tax positions in prior period	47
Reductions related to tax positions in prior period		(1,548)
Increases related to tax positions taken during the current period	0	0
Balance as of the end of the year	$ 83	$ 36

Note 17 - Income Taxes - Sche_5

Note 17 - Income Taxes - Schedule of Tax Effected Amount of Recognized Tax Position (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance as of the beginning of the year	$ (563)	$ (478)
Increases related to tax positions in prior period	0	0
Reduction (increase) related to tax position taken during the current period	210	(49)
Increase related to interest expense	(23)	(36)
Balance as of the end of the year	$ (376)	$ (563)

Note 18 - Segment and Geograp_3

Note 18 - Segment and Geographic Information (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Number of Reportable Segments	1
Number of Operating Segments	1
Leases [Member]
Sales with Typical Lease Terms (Month)	36 months
System [Member]
Sales with Payment Terms (Month)	12 months
UNITED STATES
Long-Lived Assets	$ 12,346	$ 16,090
Non-US [Member]
Long-Lived Assets	$ 1,431	$ 1,972

Note 18 - Segment and Geograp_4

Note 18 - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total revenue	$ 99,497	$ 105,622
UNITED STATES
Total revenue	52,101	51,400
Non-US [Member]
Total revenue	$ 47,396	$ 54,222

Note 18 - Segment and Geograp_5

Note 18 - Segment and Geographic Information - Schedule of Revenue by Type (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total revenue	$ 99,497	$ 105,622
Leases [Member]
Total revenue	35,267	45,094
System [Member]
Total revenue	47,906	43,106
Product [Member]
Total revenue	13,316	13,230
Service [Member]
Total revenue	$ 3,008	$ 4,192

Note 19 - Related Party Trans_2

Note 19 - Related Party Transactions (Details Textual) $ in Thousands			1 Months Ended	12 Months Ended
	Nov. 18, 2022 USD ($) shares	Dec. 15, 2021 USD ($)	Nov. 30, 2022 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020	Jan. 01, 2021	Jan. 01, 2018
Proceeds from Issuance of Private Placement		$ 16,740
Venus Concept Singapore Pte. Ltd (Venus Singapore) [Member]
Disposal Group, Including Discontinued Operation, Percentage of Ownership						55%
Voting Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Ratio			10
Senior Officer [Member] | Technicalbiomed Co., Ltd. (TBC) [Member]
Equity Method Investment, Ownership Percentage							45%	30%
Technicalbiomed Co., Ltd. (TBC) [Member]
Revenue from Related Parties				$ 951	$ 537
Venus Concept Singapore Pte. Ltd (Venus Singapore) [Member]
Revenue from Related Parties				$ 441	239
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares				7,585,529
Proceeds from Issuance of Private Placement		$ 12,074
Preferred Stock [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member] | Voting Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	3,185,000
The 2022 Private Placement [Member]
Proceeds from Issuance of Private Placement			$ 6,720	$ 6,518	$ 0
The 2022 Private Placement [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member]
Proceeds from Issuance of Private Placement	$ 6,720
The 2022 Private Placement [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member] | Voting Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Ratio	10
The 2022 Private Placement [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares			1,750,000
The 2022 Private Placement [Member] | Common Stock [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	1,750,000
The 2022 Private Placement [Member] | Preferred Stock [Member] | Chief Executive Officer, President, Chief Innovation and Business Officer, and Certain Members of the Board [Member] | Voting Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	3,185,000

Note 20 - Subsequent Events (De

Note 20 - Subsequent Events (Details Textual)			3 Months Ended	12 Months Ended
	Mar. 01, 2023 GBP (£)	Jun. 17, 2020 shares	Mar. 27, 2023 $ / shares shares	Dec. 31, 2022 shares	Jun. 30, 2022 $ / shares
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares				7,585,529
Equity Purchase Agreement [Member] | Lincoln Park [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares		3,437,087		400,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 2.70
Subsequent Event [Member] | Equity Purchase Agreement [Member] | Lincoln Park [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares			2,865,802
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 0.248
Chief Operating Officer [Member] | Subsequent Event [Member]
Severance Costs | £	£ 315,418.77
Payment for Pension and Other Postretirement Benefits, Total | £	3,400
Legal Fees | £	£ 2,000